

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ :**C07D 471/04, A61K 31/435 // (C07D 471/04, 235:00, 221:00)****A1**

(11) International Publication Number:

WO 96/25414

(43) International Publication Date:

22 August 1996 (22.08.96)

(21) International Application Number:

PCT/US96/01114

(22) International Filing Date:

12 February 1996 (12.02.96)

(30) Priority Data:

08/388,682

15 February 1995 (15.02.95)

US

(60) Parent Application or Grant

(63) Related by Continuation

US

Filed on

08/388,682 (CIP)

15 February 1995 (15.02.95)

(71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(72) Inventor; and


(75) Inventor/Applicant (for US only): TENBRINK, Ruth, E. [US/US]; 6031 North 28th Street, Richland, MI 49083 (US).

(74) Agent: GAMMILL, Martha, A.; Corporate Intellectual Property Law, Pharmacia & Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published*With international search report.*

(54) Title: IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES



(57) Abstract

The present invention relates to imidazo[1,2-a]pyridine compounds of formula (I), which are dopamine D-4 antagonists and useful as anti-psychotic agents.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

WO 96/25414

PCT/US96/01114

IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES

FIELD OF THE INVENTION

The present invention relates to imidazo[1,2-a]pyridine compounds, which are
5 dopamine D₄ antagonists, which are useful to treat and/or prevent the progression of psychotic disorders.

BACKGROUND OF THE INVENTION

Dopamine receptors mediate a number of central nervous system functions. Screening of clinical entities useful in the treatment of psychotic-like states revealed
10 that many of the so-called "atypical" antipsychotics, which are characterized by reduced or absent extrapyramidal side effects (J.A. Lowe III, *et al.*, Med. Res. Rev., 8, 475 (1988); M. Lader, J. Internat. Med. Res., 17, 1 (1989)), exhibit high binding affinities for the dopamine D₄ receptor, especially as compared to the D₂ receptor (Sokaloff, *et al.*, Biochem. Pharmacol., 43, 659 (1992); Leysen, *et al.*, Psycho-
15 pharmacology, 112, S40-S54 (1993)). Seeman *et al* (Nature, 365, 441 (1993)) found that dopamine D₄ receptors are elevated 6-fold in postmortem schizophrenic brain tissue. Several other studies using positron emission tomography (Farde, *et al.*, Arch. Gen. Psychiatry, 47, 213 (1990); Wong, *et al.*, Science, 234, 1558 (1986) also were interpreted to indicate an increase in dopamine D₄ receptor levels in
20 schizophrenics (Lahti, *et al.*, Eur. J. Pharmacol., 236, 483 (1993)). These results support the usefulness of selective, high affinity dopamine D₄ antagonists for the treatment, with reduced side effects, of psychotic-like diseases (Science, 265, 1034 (1994)). See also Meth. Find. Exp. Clin. Pharmacol. 16(5): 303-307 (1994), which discloses the receptor pharmacology of a human D₄-dopamine receptor expressed in
25 HEK 293 cells from a synthetic gene, which receptor should be useful for the discovery and study of novel dopamine antagonists and agonist ligands.

INFORMATION DISCLOSURE

U.S. Patent 3,362,956 describes bicyclic heterocycles having fused five- and six-membered rings containing from one to three nitrogen atoms which may be in
30 any position of the two rings (fourteen examples of such ring systems are given; none of which are imidazo[1,2-a]pyridines), linked to aryl piperazine with a carbon linker of one to six carbons, which are useful as tranquilizers, sedatives, adrenolytic agents, hypothermic agents, anticonvulsants, hypotensive agents, and cardiovascular agents. For example, Example 21 discloses S-triazolo[4,3-a]pyridine (or pyrido[2,1-
35 c]-s-triazole) linked to aryl piperazine with a two carbon linker at position three of the heterocycle. The heterocycles that are claimed are 3-quinoline (isoquinoline), 3,4-

WO 96/25414

PCT/US96/01114

dihydroisoquinoline, and 1,2,3,4-tetrahydroisoquinoline. U.S. Patent 3,511,841 discloses 1-[(4-, 5-, 6-, and 7-azaindolyl)-lower-alkyl]-4-substituted-piperazines which are indicated as being useful as tranquilizers, sedatives, skeletal muscle relaxants, adrenolytics, hypothermic agents, anti-convulsants, hypotensives, and cardiovascular agents.

The compounds of the present invention are imidazo[1,2-a]pyridines with a one carbon linker at position two of the heterocycle, which are useful as dopamine D₄ antagonists. For the present invention, it is necessary that the imidazo[1,2-a]pyridine portion of the molecule not be linked to aryl piperazine by a two carbon chain; the two carbon analog was inactive in binding to dopaminergic receptors.

WO 94/20497 discloses pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, which are selective dopamine D₄ antagonists and are expected to be of benefit in the treatment of psychotic disorders such as schizophrenia.

The compounds of the present invention are imidazo[1,2-a]pyridines substituted at the two-position by an aryl-piperazinylmethyl moiety.

WO 94/22839 discloses benzimidazole derivatives, substituted at the 2-position by a substituted piperazinylmethyl or piperazinylethyl moiety, which are selective dopamine D₄ antagonists and are expected to be of benefit in the treatment of psychotic disorders such as schizophrenia.

The compounds of the present invention are imidazo[1,2-a]pyridines substituted at the two-position by an aryl-piperazinylmethyl moiety.

U.S. Patent 3,472,854 discloses 1-[(1- or 2-benzimidazolyl)-lower-alkyl]-4-substituted piperazines, which are useful as tranquilizers, sedatives, skeletal muscle relaxants, adrenolytics, hypothermic agents, anti-convulsants, hypotensives and cardiovascular agents. U.S. Patent 3,658,822 discloses (benzimidazolyl-2-methyl)-piperazine derivatives, which exhibit cardiotropic activity, analgesic activity, sedative activity and spasmolytic activity.

The compounds of the present invention are imidazo[1,2-a]pyridines substituted at the two-position by an aryl-piperazinylmethyl moiety, which are useful as dopamine D₄ antagonists.

Derwent Abstracts 10911 K/05 and 34368B/18 of J 57206685 and J 54039093, respectively (as well as English translations thereof), disclose S-triazolo[1,5-a]pyridines with a carbon chain linker to aryl piperazine, in which the carbon chain may be from one to five carbons, useful for the treatment of hypertension and for treating respiratory and circulatory system diseases. U.S. patent 4,202,977 relates

WO 96/25414

PCT/US96/01114

to S-triazolo[1,5-a]pyridines linked to aryl piperazine with a carbon chain of three or five carbons, which are useful for the treatment of hypertension.

The compounds of the present invention are imidazo[1,2-a]pyridines and the linker to the aryl piperazine is one carbon only, and active as dopamine D₄

5 antagonists.

U.S. Patent 4,910,199 (English language equivalent of Eur. Pat. Appl. 306,408) discloses imidazo[1,2-b]pyridazines linked to various amines with a one-carbon chain. The amine may be, for example, an alkyl amine, morpholine, piperidine, or pyrrolidine. The compounds are useful for the treatment of cortical
10 cholinergic deficits.

The compounds of the present invention are imidazo[1,2-a]pyridines, which when linked to piperazine must have an aryl group or an amino aryl group directly attached to the second nitrogen of the piperazine. When linked to piperidine, the piperidine must have an aryl group or an aminoaryl group attached at position four.
15 The compounds of the present invention are also dopamine D₄ antagonists.

U.S. Pat. 4,988,698 discloses imidazo[1,2-a]pyridines with attached piperazinyl-2(1H)-quinolinones, useful for the treatment of heart diseases and hypertension, wherein the linker between the imidazo[1,2-a]pyridine and the piperazinyl-2(1H)-quinolinone is an amide or an alcohol.

20 The compounds of the present invention contain neither amide nor alcohol linkers nor quinolinones attached at piperazine, and are useful as dopamine D₄ antagonists.

U.S. Pat. 3,381,009 discloses triazolo[4,3-a]pyridin-3-ones connected to aryl piperazine with a three carbon linker, useful for their tranquilizing, hypotensive,
25 and analgesic actions.

The compounds of the present invention do not contain a keto group at the three-position, are not triazolo[4,3-a]pyridines, and have only one carbon as a linker. Also they are useful as dopamine D₄ antagonists.

WO 92-17475-A1 discloses benzoxazoles and indazoles linked at position
30 three with a carbon chain of one to three carbons to aryl piperazine, useful as cholinesterase inhibitors for the treatment of dementia and Alzheimer's disease and for improving memory.

The compounds of the present invention are imidazo[1,2-a]pyridines and are linked to the aryl piperazine with a one carbon chain at position two. They are also
35 useful as dopamine D₄ antagonists.

WO 95/07262, published 16 March 1995 (PCT filing date of 6 September

WO 96/25414

PCT/US96/01114

1994), discloses benzo[g]indazoles which are dopamine D4 ligands and useful in the treatment of schizophrenia, depression, Parkinson's disease and tardive dyskinesias.

WO 95/29911, published 9 November 1995 (Great Britain priority date of 28 April 1994), discloses benzo[b]furans which are selective antagonists at the dopamine D4 receptor and useful in the treatment of schizophrenia.

WO 94/20471, published 15 September 1994, discloses quinolines which bind to the D4 receptor and are useful for the treatment of psychotic disorders, particularly schizophrenia.

SUMMARY OF THE INVENTION

The present invention provides:

A compound of the formula I wherein R_1 and R_2 are the same or different and are

- a) H,
- 15 b) fluoro,
- c) chloro,
- d) bromo,
- e) iodo,
- f) C_1-C_4 alkyl,
- 20 g) C_3-C_7 cycloalkyl,
- h) CN,
- i) $CONR_{11}R_{12}$,
- j) $SO_2NR_{11}R_{12}$,
- k) $NR_{11}R_{12}$,
- 25 l) $N(R_{11})SO_2R_{12}$,
- m) $N(R_{11})CO(R_{12})$,
- n) NO_2 ,
- o) OH,
- p) $O(C_1-C_3 \text{ alkyl})$,
- 30 q) O-phenyl,
- r) O- CF_3 ,
- s) O- SO_2CF_3 ,
- t) SH,
- u) $S(C_1-C_3 \text{ alkyl})$,
- 35 v) thiazolyl,
- w) imidaz lyl,

WO 96/25414

PCT/US96/01114

- x) oxadiazolyl,
- y) aryl optionally substituted with R_{13} , or
- z) CF_3 ;

wherein R_3 is

- 5 a) H,
- b) halo,
- c) CN,
- d) OH,
- e) OR_4 ,
- 10 f) $(CH_2)_n OH$,
- g) $(CH_2)_n OR_4$,
- h) $(CH_2)_n OCOR_4$,
- i) $(CH_2)_n OCOOR_4$,
- j) $(CH_2)_n OCONR_{11}R_{12}$,
- 15 k) $(CH_2)_n N(R_{11})CONR_{11}R_{12}$,
- l) C_1-C_4 alkyl,
- m) $(CH_2)_p COOR_4$,
- n) $(CH_2)_n CONR_{11}R_{12}$,
- o) CHO, or
- 20 p) $(CH_2)_n -A-(CH_2)_m -Ar(R_8)(R_9)(R_{10})$;

wherein A is

- a) CH_2 ,
- b) O,
- c) S, or
- 25 d) $N(R_{11})$;

wherein R_4 , R_5 , R_6 and R_7 are the same or different and are

- a) H,
- b) C_1-C_4 alkyl,
- c) C_3-C_7 cycloalkyl,
- 30 d) C_1-C_3 -alkyl- C_3-C_7 cycloalkyl, or
- e) aryl optionally substituted with R_{13} ;

wherein W is

- a) N, or
- b) CH;
- 35 wherein X is
- a) absent. or

WO 96/25414

PCT/US96/01114

b) $N(R_4)$;

wherein Y is

- a) phenyl,
- b) 2-, 3- or 4-pyridinyl,
- 5 c) 2-, 4- or 5-pyrimidinyl,
- d) 3- or 4-pyridazinyl,
- e) 2-pyrazinyl,
- f) 2-, 3-, 6- or 7-imidazo[1,2-a]pyridinyl,
- g) 2-benzoxazolyl,
- 10 h) 2-thiobenzoxazolyl,
- i) 2-thiazolyl,
- j) 1,3-dihydro-2H-benzimidazol-2-one, or
- k) 1,3-dihydro-3-methyl-2H-benzimidazol-2-one;

wherein R_8 , R_9 and R_{10} are the same or different and are

- 15 a) hydrogen,
- b) fluoro,
- c) chloro,
- d) bromo,
- e) iodo,
- 20 f) C_1 - C_4 alkyl,
- g) C_3 - C_7 cycloalkyl,
- h) CN,
- i) $CONR_{11}R_{12}$
- j) $SO_2NR_{11}R_{12}$,
- 25 k) $NR_{11}R_{12}$,
- l) $N(R_{11})SO_2R_{12}$,
- m) $N(R_{11})COR_{12}$,
- n) NO_2 ,
- o) OH,
- 30 p) $O(C_1$ - C_3 alkyl),
- q) O-aryl optionally substituted with R_{13} ,
- r) $O-CF_3$,
- s) $O-SO_2CF_3$,
- t) SH,
- 35 u) $S(C_1$ - C_3 alkyl),
- v) thiazolyl,

WO 96/25414

PCT/US96/01114

- w) imidazolyl,
x) oxadiazolyl,
y) phenyl, or
z) 2-, 3- or 4-pyridinyl;
5 a1) CF_3 ,
b1) $-\text{C}(\text{O})\text{C}_1\text{-C}_4\text{alkyl}$,
c1) $\text{C}(\text{O})\text{OR}_4$, or
d1) SO_2 -phenyl optionally substituted with R_{13} ;
wherein R_{11} and R_{12} are the same or different and are
10 a) H,
b) $\text{C}_1\text{-C}_4$ alkyl,
c) $\text{C}_3\text{-C}_7$ cycloalkyl,
d) $\text{C}_1\text{-C}_3$ alkyl- $\text{C}_3\text{-C}_7$ cycloalkyl, or
e) aryl optionally substituted with R_{13} ;
15 when R_{11} and R_{12} occur in $\text{NR}_{11}\text{R}_{12}$, R_{11} and R_{12} may be taken together with a methylene group or a heteroatom to form a five- or six-membered ring, such as piperazine, morpholine, thiomorpholine, piperidine, or pyrrolidine;
wherein aryl is
a) phenyl,
20 b) naphthyl,
c) 2-, 3- or 4-pyridinyl, or
d) 2-, 4- or 5-pyrimidinyl;
wherein R_{13} is
a) H,
25 b) fluoro,
c) chloro,
d) bromo,
e) iodo,
f) CH_3 ,
30 g) CF_3 ,
h) CN,
i) OH, or
j) OCH_3 ;
wherein n is one (1) to four (4) inclusive;
35 wherein m is zero (0) to four (4) inclusive;
wherein p is two (2) to four (4) inclusive;

WO 96/25414

PCT/US96/01114

and pharmaceutically acceptable salts and racemic mixtures thereof;

with the following provisos:

- 1) when R_1 or R_2 is $-\text{CONR}_{11}\text{R}_{12}$, then R_{11} and R_{12} are not both H; and
- 2) when R_8 , R_9 or R_{10} is $-\text{CONR}_{11}\text{R}_{12}$ wherein R_{11} and R_{12} are both H.

5 then X is absent.

More particularly, the present invention provides:

The compound of the formula II wherein R_1 and R_2 are the same or different

and are

- a) H,
- 10 b) chloro,
- c) bromo,
- d) CH_3
- e) $\text{O}(\text{C}_1\text{-C}_2 \text{ alkyl})$,
- f) phenyl, or
- 15 g) CF_3 ;

wherein R_3 is

- a) H,
- b) $(\text{CH}_2)\text{OH}$, or
- c) $\text{CH}_2\text{-O-CH}_2\text{-phenyl}$;

20 wherein R_6 is

- a) H, or
- b) CH_3 ;

wherein W is

- a) N, or
- 25 b) CH;

wherein Y is

- a) phenyl,
- b) 2-pyridinyl,
- c) 2-pyrimidinyl,
- 30 d) 1,3-dihydro-2H-benzimidazol-2-one, or
- e) 1,3-dihydro-3-methyl-2H-benzimidazol-2-one;

wherein R_8 and R_9 are the same or different and are

- a) hydrogen,
- b) fluoro,
- 35 c) chloro,
- d) CN,

WO 96/25414

PCT/US96/01114

- e) CONH_2
f) OCH_3 ,
g) CF_3 ,
h) C(O)CH_3 , or
5 i) SO_2NH_2 ;

and pharmaceutically acceptable salts and racemic mixtures thereof.

Even more particularly, the present invention provides:

The compound of the formula III wherein R_1 and R_2 are the same or different and are

- 10 a) H,
b) chloro,
c) bromo,
d) CH_3 ,
e) OCH_3 ,
15 f) OCH_2CH_3 ,
g) phenyl, or
h) CF_3 ;

wherein R_3 is

- a) H,
20 b) CH_2OH ,
c) $\text{CH}_2\text{-O-CH}_2\text{-phenyl}$;

wherein R_6 is

- a) H, or
b) CH_3 ;
25 wherein R_8 and R_9 are the same or different and are:

- a) hydrogen,
b) fluoro,
c) chloro,
d) CN,
30 e) CONH_2 ,
f) OCH_3 ,
g) CF_3 ,
h) C(O)CH_3 , or
i) SO_2NH_2 ;

35 and pharmaceutically acceptable salts and racemic mixtures thereof.

Most particularly, the present invention provides:

WO 96/25414

PCT/US96/01114

The compound of the formula IIIA wherein R_1 is

- a) H,
- b) bromo,
- c) chloro, or
- 5 d) CH_3 ;

wherein R_8 and R_9 are the same or different and are

- a) H or
- b) chloro;

and pharmaceutically acceptable salts and racemic mixtures thereof.

10 Also most particularly, the present invention provides:

The compound of the formula IV wherein R_2 is chloro;

wherein Y is

- a) phenyl,
- b) 1,3-dihydro-2H-benzimidazol-2-one, or
- 15 c) 1,3-dihydro-3-methyl-2H-benzimidazol-2-one;

and pharmaceutically acceptable salts and racemic mixtures thereof.

Also, most particularly, the present invention provides:

The compound of the formula V wherein R_2 is chloro;

wherein Y is

- 20 a) 2-pyridinyl, or
- b) 2-pyrimidinyl;

wherein R_8 and R_9 are the same or different and are

- a) H,
- b) Cl, or
- 25 c) CF_3 ;

and pharmaceutically acceptable salts and racemic mixtures thereof.

Furthermore, the present invention also provides:

A method for treating a patient having a disease associated with the dopaminergic system of the central nervous system or the heart which comprises:

30 administering an effective amount of a compound of formula I of claim 1.

More particularly, the present invention provides such method wherein the disease is selected from the group consisting of: schizophrenia, psychosis, depression, anxiety, drug addiction, and cardiac arrhythmias and fibrillation.

Finally, the present invention also provides:

35 A method for lessening the extrapyramidal motor side effects in a patient, who is being treated with an anti-psychotic drug, which comprises:

WO 96/25414

PCT/US96/01114

administering to the patient an effective amount of a compound of formula I.

More particularly, the present invention provides such method wherein the anti-psychotic drug is selected from the group consisting of chlorpromazine, thioridazine, haloperidol, and risperidone.

5 Also, more particularly, the present invention provides such method wherein the dose of the anti-psychotic drug is administered at a higher dose than when the drug is administered alone.

The present invention provides compounds of the formula I and enantiomers and diastereomers thereof where such exist and pharmaceutically acceptable salts
10 thereof to prepare a medicament to treat humans who are in need of treatment for psychosis, paraphrenia, psychotic depression, mania, dementia, schizophrenia, schizophreniform disorders, vascular headaches, migraine headaches, anxiety, drug addiction, convulsive disorders, spectrum disorders, personality disorders, attention deficit disorders in children and adults, post traumatic stress syndrome, dysthymia
15 and extrapyramidal motor side effects of other antipsychotic (neuroleptic) drugs, such as haloperidol (see Conn's Current Therapy, R. Rakel, ed., (1994) pp. 1122-1126, Table 1).

The compounds of the present invention are named according to the IUPAC or CAS nomenclature system.

20 The carbon atoms content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C_i-C_j indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive. Thus, for example, C_1-C_3 alkyl refers to alkyl of one to three carbon atoms, inclusive, or methyl, ethyl, propyl, and isopropyl, straight
25 and branched forms thereof.

Also, the carbon atom content of various hydrocarbon-containing moieties of the present invention is indicated by a subscripted integer representing the number of carbon and hydrogen atoms in the moiety, e.g., " $(CH_2)_n$ " indicates that the moiety " CH_2 " is taken "n" times. Thus, for example, " $(CH_2)_n$ " wherein n is one to three,
30 inclusive, represents the straight forms of methyl, ethyl and propyl.

Examples of alkyl of one to nine carbon atoms, inclusive, are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, and nonyl, and all isomeric forms thereof and straight and branched forms thereof.

Examples of alkenyl of one to five carbon atoms, inclusive, are ethenyl,
35 propenyl, butenyl, pentenyl, all isomeric forms thereof, and straight and branched forms thereof.

WO 96/25414

PCT/US96/01114

By "halo" is meant the typical halogen atoms, such as fluorine, chlorine, bromine, and iodine.

The chemical formulas representing various compounds or molecular fragments in the specification and claims may contain variable substituents in addition to expressly defined structural features. These variable substituents are identified by a letter or a letter followed by a numerical subscript, for example, "Z" or "R₁" where "1" is an integer. These variable substituents are either monovalent or bivalent, that is, they represent a group attached to the formula by one or two chemical bonds. For example, a group Z would represent a bivalent variable if attached to the formula CH₃-C(=Z)H. Groups R₁ and R₂ would represent monovalent variable substituents if attached to the formula CH₃-CH₂-C(R₁)(R₂)-H. When chemical formulas are drawn in a linear fashion, such as those above, variable substituents contained in parentheses are bonded to the atom immediately to the left of the variable substituent enclosed in parenthesis. When two or more consecutive variable substituents are enclosed in parentheses, each of the consecutive variable substituents is bonded to the immediately preceding atom to the left which is not enclosed in parentheses. Thus, in the formula above, both R₁ and R₂ are bonded to the preceding carbon atom.

Chemical formulas or portions thereof drawn in a linear fashion represent atoms in a linear chain. The symbol "-" in general represents a bond between two atoms in the chain. Thus CH₃-O-CH₂-CH(R₁)-CH₃ represents a 2-substituted-1-methoxypropane compound. In a similar fashion, the symbol "=" represents a double bond, e.g., CH₂=C(R₁)-O-CH₃, and the symbol "≡" represents a triple bond, e.g., HC≡C-CH(R₁)-CH₂-CH₃. Carbonyl groups are represented in several ways, for example: -C(O)-, -CO- or -C(=O)-.

The compounds of formula I of the present invention are prepared as described in the Charts, wherein the variables are as defined above or are indicated below, and Examples below, or are prepared by methods analogous thereto, which are readily known and available to one of ordinary skill in the art of organic synthesis, e.g., in PCT Application No. PCT/US94/13284, filed 30 November 1994, which is incorporated by reference herein.

CHART A

Amino pyridine A-2 is prepared in several steps from pyridine A-1, which is commercially available, by the method of Lombardino, J. Med. Chem. 24:39 (1981).

R₁ is a straight-chained or branched alkyl group.

CHART B

WO 96/25414

PCT/US96/01114

Bis(ethyl)amine B-b is prepared from bis amine B-a (commercially available) by treatment with an amine protecting group known to those skilled in the art, such as tert-butyloxycarbonyl or benzyloxycarbonyl. Bis(ethyl)amine B-1 is either available commercially (wherein X is Cl, Br), or from bis(ethyl)amine B-b by commonly used methods known to those skilled in the art. R₈ and R₉ are H, halo, alkyl, cycloalkyl, cyano, amino (including substituted amino), OH, O-alkyl and O-aryl. When R₈ and R₉ are strongly electron-withdrawing groups, B-3 is better made by other routes, such as those described in Chart C below or other methods known to one of ordinary skill in the art.

Aryl piperazine B-3 is prepared by heating bis(ethyl)amine B-1, wherein X is chloro, bromo, iodo, O-mesylate, or O-tosylate, in the presence of aniline B-2 with or without added base such as potassium carbonate or diisopropylethylamine, and using solvents such as DMF, THF, N,N-dimethylacetamide, or N-methyl-2-pyrrolidinone.

CHART C

Aryl piperazine C-3 is prepared by heating piperazine C-1 in the presence of fluoroaryl C-2 in solvents such as water, DMF, N-methyl-2-pyrrolidinone, THF, ethyl acetate, acetonitrile, N,N-dimethylacetamide, or dioxane, at temperatures of 80 to 200 °C. When piperazine C-1 is used in an excess of two or more equivalents, no added base is necessary. When a single equivalent of piperazine C-1 is present, added base such as diisopropylethyl amine or potassium carbonate is used. Either R₈ or R₉ or both are electron-withdrawing groups and one of R₈ or R₉ is in either the ortho or para position relative to the fluorine atom. R₆ and R₇ are C₁-C₄ alkyl.

CHART D

Imidazopyridine D-3 is prepared from aminopyridine D-1 or the amino pyridine A-2 (refer to Chart A) and 3-halopyruvate ester D-2 (wherein halo is chloro, bromo, iodo, mesylate or tosylate) either by a two-step procedure whereby D-1 (or A-2) and D-2 are stirred in a solvent such as dimethoxyethane with or without the addition of a base such as triethylamine or potassium carbonate. The solvent is then replaced with alcoholic solvent such as methanol, ethanol, isopropanol, or tert-butanol and the mixture is heated until no additional D-3 is formed.

Alternatively, alcohol is added as a co-solvent to the mixture followed by heating until no more D-3 is formed. In some cases it is more convenient to stir D-1 and D-2 in dimethoxyethane, without added base, and collect the resulting solid D-3 and wash it with a small amount of dimethoxyethane or diethyl ether. The solid is then taken up in alcoholic solvent, and the mixture is heated until no more D-3 is

WO 96/25414

PCT/US96/01114

formed.

Hydrolysis of D-3 with aqueous hydroxide, followed by acidification, gives carboxylic acid D-4. Carboxylic acid D-4 is condensed with aryl piperazine (refer to Chart B, B-3, and Chart C, C-3, or commercially available aryl piperazine) using a coupling reagent such as diethylcyanophosphonate, dicyclohexylcarbodiimide, carbonyl diimidazole, or ethyldimethylaminopropylcarbodiimide, to give amide D-5.

Alternatively, carboxylic acid D-4 is treated with thionyl chloride or oxalyl chloride/DMF to give an acid chloride, which is then combined with aryl piperazine to give amide D-5.

Amide D-5 is reduced to the final product, imidazopyridine alkane D-6, when R_1 , R_8 , and R_9 are non-reducible groups, with reducing agents such as lithium aluminum hydride, borane, or borane-methyl sulfide in solvents such as THF or ethyl ether. When R_1 , R_8 , and R_9 are reducible groups, the final product, D-6 is prepared by the method of Chart E, described below. R_1 , R_8 and R_9 are, e.g., H, alkyl, halo, amino, OH, O-alkyl, OCF_3 , OSO_2CF_3 , SH, S-alkyl.

CHART E

Imidazopyridine salt E-3 is prepared from aminopyridine E-1 (also D-1) (refer to Chart D) (commercial source) or the amino pyridine A-2 (refer to Chart A) and dihaloacetone E-2 (Aldrich) either by a two-step procedure whereby E-1 and E-2 are stirred in a solvent such as dimethoxyethane with or without the addition of a base such as triethylamine or potassium carbonate to give imidazopyridine salt E-3. If dimethoxyethane alone is used as solvent, it is then replaced with alcoholic solvent and E-3 is heated until no additional E-4 is formed.

Alternatively, alcoholic solvent is added as a co-solvent to the dimethoxyethane mixture of E-3, followed by heating until no additional E-4 is formed.

In some cases it is more convenient to stir E-1 (or A-2) and E-2 in dimethoxyethane, without added base, and collect the resulting solid E-3 and wash it with a small amount of dimethoxyethane to remove by-products or unreacted starting material.

Imidazopyridine E-3 is then taken up in alcoholic solvent and the mixture is heated until no more haloimidazopyridine E-4 is formed. Haloimidazopyridine E-4 is then reacted with aryl piperazine B-3 (refer to Chart B) or C-3 (refer to Chart C) or commercially available aryl piperazine to give final product, imidazopyridine alkane E-5 (also D-6) (refer to Chart D). R_1 , R_6 , R_7 , R_8 and R_9 are as defined above.

CHART F

W 96/25414

PCT/US96/01114

Imidazopyridine carboxamide F-2 is prepared from imidazopyridine nitrile F-1 by the general method of Hall and Gisler, J. Org. Chem. 41:3769 (1976) and references cited therein, via hydrolysis of the nitrile with sodium hydroxide in tert. butanol with warming and with the addition of aq. hydrogen peroxide, to give final product, imidazopyridine carboxamide F-2. R_1 , R_6 , R_7 and R_8 are as defined above, except R_1 and R_8 are not -CN.

CHART G

Imidazopyridine alkane G-1 (also D-6 and E-5 in Charts D and E above) is stirred in formalin (37% formaldehyde in water) with THF as cosolvent to give final product, imidazopyridine alcohol G-2. Imidazopyridine alcohol G-2 is reacted with a base such as sodium or potassium hydride in solvents such as THF or DMF. The resulting alkoxide intermediate is alkylated with a haloalkylaryl to give final product, imidazopyridine ether G-3. R_1 , R_6 , R_7 , R_8 and R_9 are as defined above except they are not -OH or -SO₂NH₂.

CHART H

Final product, imidazopyridine biphenyl H-2 is prepared from imidazopyridine bromide H-1 (prepared by the method of Chart E, wherein E-1 is commercially available) by the method of Yang and Martin, Heterocycles 34:1395 (1992) and references cited therein. R_3 , R_6 , R_7 , R_8 and R_9 are as defined above except they are not -Br.

CHART I

Chart I discloses a method whereby arylaminopiperidines I-5 are prepared from commercially available protected piperidinone I-1. Protected piperidinone I-1 is reacted with a substituted amine I-2 in a reductive amination in the presence of sodium cyanoborohydride in methanol or hydrogen and palladium on carbon catalyst in methanol to give the protected aminopiperidine I-3. Aminopiperidine I-3 is then reacted with an appropriate halogenated (substituted) aryl group in the presence of added base such as diisopropylethylamine or excess protected aminopiperidine I-3 to form the arylaminopiperidine I-4. The protecting group is removed by methods known to those skilled in the art, such as reacting I-4 in the presence of hydrogen with palladium catalyst to give arylaminopiperidine I-5. R_4 is, e.g., H or alkyl; aryl is, e.g., Ph, pyridinyl, pyrimidinyl which are not substituted with CONH₂.

CHART J

Chart J discloses a method of preparing arylpiperidines J-5 from commercially available protected piperidinone J-1. Protected piperidinone J-1 is reacted with a Grignard reagent (e.g., ArMgBr) by methods known to those skilled

WO 96/25414

PCT/US96/01114

in the art to give piperidine alcohol J-2. Piperidine alcohol J-2 is then treated under dehydrating conditions such as aq. hydrochloric acid to give unsaturated piperidine J-3. The unsaturation is then removed using hydrogenation in the presence of palladium catalyst to give protected aryl piperidine J-4. The protecting group is
5 then removed, preferably using the method of Olofson (J. Org. Chem., 49:2081 and 2795 (1984)), to give arylpiperidine J-5. Ar is, e.g., phenyl, pyridinyl or pyrimidinyl.

CHART K

Amide K-2 is prepared from amide K-1 by first treating amide K-1 (Chart E) in an aprotic solvent such as THF or DMF with a strong base such as sodium
10 hydride, potassium hydride, potassium tert-butoxide, or LDA and then adding an alkylhalide or alkyl triflate to the mixture. R_1 , R_2 , R_3 , and R_8 should not contain abstractable protons (and, e.g., are not CONH_2 , SO_2NH_2 , OH, SH). R^* in K-2 is alkyl.

The imidazo[1,2-a]pyridines of formula I may contain an asymmetric center
15 and therefore produce two enantiomers one "S" which is (-) and the other "R" which is (+). In some cases both enantiomers (+) and (-) are useful in the same way as the optically impure (racemic, \pm) mixture. Hence, they may be utilized in the racemic form without separating them. However, if it is desired to utilize one of the enantiomers, the optically impure mixture can be resolved by means known to those
20 skilled in the art. It is preferable to prepare the piperazine in chiral form or to resolve the substituted piperazine prior to its incorporation into the rest of the molecule using methods known to those skilled in the art, see for example, Optical Resolution Procedures for Chemical Compounds, Vol 1.: Amines and Related
Compounds, Paul Newman, Optical Resolution Information Center, Manhattan
25 College, Riverdale, NY, 10471, 1978. These optically pure compounds are then used in the same way as the racemic mixture. When used in this patent application the term "imidazo[1,2-a]pyridines" of formula I refers to and includes both enantiomers as well as optically impure forms thereof, the most common of which is a racemic mixture (\pm , dl).

30 Some imidazo[1,2-a]pyridines of formula I contain two asymmetric centers and therefore four enantiomers (SS, RR, SR, RS) exist producing two diastereomeric pairs of enantiomers, one SS,RR and the other SR,RS. The diastereomeric pairs of enantiomers can be readily separated by means known to those skilled in the art. When used in this patent application the term "imidazo[1,2-a]pyridines" of formula I
35 includes all four enantiomers as well as optically impure forms thereof, the most common of which is a racemic mixture (\pm).

WO 96/25414

PCT/US96/01114

The imidazo[1,2-a]pyridines of formula I are bases, and as such form acid addition salts when reacted with acids of sufficient strength. Pharmaceutically acceptable salts include salts of both inorganic and organic acids. The pharmaceutically acceptable salts are preferred over the corresponding free amines since they produce compounds which are more water soluble and more crystalline. Pharmaceutically acceptable salts refers to those salts which would be readily apparent to a manufacturing pharmaceutical chemist to be equivalent to the parent compound in properties such as formulation, stability, patient acceptance and bioavailability. The preferred pharmaceutically acceptable salts include salts of the following acids: methanesulfonic, hydrochloric (mono and di), hydrobromic, sulfuric, phosphoric, nitric, benzoic, hexamic, citric, tartaric, fumaric, maleic, $\text{CH}_3\text{-(CH}_2)_t\text{-COOH}$, or $\text{HOOC-(CH}_2)_t\text{-COOH}$, wherein t is 0 through 4. See P.L. Gould, "Salt Selection for Basic Drugs," International Journal of Pharmaceutics (1986), 33:201-217, see Table 1.

The compounds of the present invention may be in either free form or in protected form, as included in the claims where appropriate, at one or more of the remaining (not previously protected) carboxyl, amino, hydroxy, or other reactive groups. The protecting groups may be any of those known in the art. Examples of nitrogen and oxygen protecting groups are set forth in T. W. Greene, Protecting Groups in Organic Synthesis, Wiley, New York, (1981); J. F. W. McOmie, ed. Protective Groups in Organic Chemistry, Plenum Press (1973); and J. Fuhrhop and G. Benzlin, Organic Synthesis, Verlag Chemie (1983). Included among the nitrogen protective groups are t-butoxycarbonyl (BOC), benzyloxycarbonyl, acetyl, allyl, phthalyl, benzyl, benzoyl, trityl and the like.

The compounds of the present invention being antagonists of dopamine receptor subtypes within the brain, are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia. Thus, the compounds of this invention are useful for the treatment and/or prevention of diseases associated with the dopaminergic system of the central nervous system and the heart, for example schizophrenia, psychosis, dementia, confusional states, depression, anxiety, drug addiction, and cardiac arrhythmias and fibrillation. The compounds are also useful in combination with other drugs used in the treatment of schizophrenia and psychosis, in particular for the mitigation of motor side effects caused by these other drugs. Moreover, the compounds of the present invention have a selective affinity for the dopamine D_4 receptor subtype over other dopamine receptor subtypes, in particular the D_2 subtype, and can therefore be expected to

WO 96/25414

PCT/US96/01114

manifest fewer or reduced side-effects than those associated with classical neuroleptic drugs.

The imidazo[1,2-a]pyridines of formula I of this invention possess selective pharmacological properties and are useful in treating humans who have a central nervous system disorders, including, for example, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, and schizophreniform disorders. An amount of the imidazo[1,2-a]pyridine (I) effective to treat the central nervous system is administered to humans in need of such treatment. Other central nervous system disorders which are treated with the imidazo[1,2-a]pyridines (I) include, for example, anxiety, drug addiction, convulsive disorders, spectrum disorders, personality disorders, attention deficit disorders in children and adults, post traumatic stress syndrome and dysthymia. Additionally, the compounds are useful as cognition enhancers. With regard to schizophrenia the imidazo[1,2-a]pyridines (I) are useful to treat psychotic, affective, psychomotor and vegative symptoms of schizophrenia.

The compounds are also useful in combination with other anti-psychotic drugs such as drugs used in the treatment of schizophrenia. For examples of these other drugs, please refer to Conn's Current Therapy, R. Rakel, ed. (1994) pp. 1122-1126, Table 1, which is incorporated by reference herein. In Table 1 of the reference, chlorpromazine and thioridazine are examples of the class, phenothiazines; haloperidol is an example of the class, butyrophenones; risperidone is an example of the class, benzisoxazole. The compounds of the present invention are useful to treat the extrapyramidal motor side effects of other antipsychotic (neuroleptic) drugs. This action will allow higher doses of the latter compounds to be used and greater antipsychotic efficacy to be obtained as a result of the reduction in dose limiting side effects.

In addition to their central nervous system pharmacological activities, the compounds of this invention are also useful in treating cardiac arrhythmias and cardiac fibrillation.

In clinical practice the imidazo[1,2-a]pyridines (I) of the present invention will normally be administered orally, rectally or by injection in the form of pharmaceutical compositions containing the active ingredient either as a free base or as a pharmaceutically acceptable acid addition salt in association with one or more pharmaceutically acceptable carriers.

For therapeutic treatment of central nervous system disorders the suitable daily effective amount of the imidazo[1,2-a]pyridines (I) are from about 0.005 to about 50 mg/kg for oral application, preferably from about 0.1 to about 30 mg/kg,

WO 96/25414

PCT/US96/01114

and from about 0.05 to about 20 mg/kg for parenteral application, preferably from about 0.1 to about 10 mg/kg. The use and administration to a patient to be treated in the clinic would be readily apparent to a person of ordinary skill in the art.

For purposes of treating cardiac arrhythmias and fibrillation, the imidazo[1,2-
5 a]pyridines (I) will normally be given orally, rectally or by injection. The daily effective amount of the imidazo[1,2-a]pyridines (I) for cardiac purposes is from about 1 to about 300 mg/kg for oral administration, preferably from about 1 to about 50 mg/kg. When given parenterally the dose is from about 0.1 to about 100 mg/kg, preferably from about 0.5 to about 50 mg/kg.

10 The exact dosage and frequency of administration depends on the particular imidazo[1,2-a]pyridine (I) used, the particular condition being treated, the severity of the condition being treated as well as the age, weight, and general physical condition of the particular patient, including other medication the patient may be taking. The exact dosage and frequency of administration would be well known to
15 those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the imidazo[1,2-a]pyridine (I) in the patient's blood and/or the patient's response to the particular condition being treated.

Those skilled in the art would know how to formulate the compounds of this invention into appropriate pharmaceutical dosage forms. Examples of the dosage
20 forms include oral formulations, such as tablets or capsules, solutions or suspensions, or parenteral formulations, such as sterile solutions.

Either solid or fluid dosage forms can be prepared for oral administration. Solid compositions are prepared by mixing the compounds of this invention with conventional ingredients such as talc, magnesium stearate, dicalcium phosphate,
25 magnesium aluminum silicate, calcium sulfate, starch, lactose, acacia, methyl cellulose, or functionally similar pharmaceutical diluents and carriers. Capsules are prepared by mixing the compounds of this invention with an inert pharmaceutical diluent and placing the mixture into an appropriately sized hard gelatin capsule. Soft gelatin capsules are prepared by machine encapsulation of a slurry of the
30 compounds of this invention with an acceptable inert oil such as vegetable oil or light liquid petrolatum. Syrups are prepared by dissolving the compounds of this invention in an aqueous vehicle and adding sugar, aromatic flavoring agents and preservatives. Elixirs are prepared using a hydroalcoholic vehicle such as ethanol, suitable sweeteners such as sugar or saccharin and an aromatic flavoring agent.
35 Suspensions are prepared with an aqueous vehicle and a suspending agent such as acacia, tragacanth, or methyl cellulose.

WO 96/25414

PCT/US96/01114

When the compounds of this invention are administered parenterally, they can be given by injection or by intravenous infusion. Parenteral solutions are prepared by dissolving the compounds of this invention in aqueous vehicle and filter sterilizing the solution before placing in a suitable sealable vial or ampule.

- 5 Parenteral suspensions are prepared in substantially the same way except a sterile suspension vehicle is used and the compounds of this invention are sterilized with ethylene oxide or suitable gas before it is suspended in the vehicle.

The exact route of administration, dose, or frequency of administration would be readily determined by those skilled in the art and is dependant on the age,
10 weight, general physical condition, or other clinical symptoms specific to the patient to be treated.

The compounds useful in this invention potently inhibit [^3H]-spiperone binding to human dopamine D_4 receptor subtypes expressed in clonal cell lines.

- [^3H]-Spiperone Binding Studies: Competition binding experiments employ
15 drug concentrations in duplicate. [^3H]-Spiperone (96Ci/mmol) is used at final concentrations of 200-800 pM. Non-specific binding (80-90% of total) is determined with 3 μM haloperidol. Binding mixtures are made in 96-deep well titer dishes (Beckman) by the addition of 50 μl of drug, 50 μl of radioligand, and 800 μl of membranes (20-60 μg protein) in binding buffer. Reactions are stopped by vacuum
20 filtration with a Tom Tec harvester. Counting is with a 1205 Beta-plate (Wallac) using MeltiLex B/HS (Wallac) as scintillant. IC_{50} values are estimated by fitting the data to a one-site model by non-linear least squares minimization. Inhibition constants (K_i) values are calculated with the Cheng-Prushoff equation. Further details of this assay are contained in Meth. Find. Exp. Clin. Pharmacol. 16(5):303-
25 307 (1994), which is hereby incorporated by reference herein.

The compounds of the following examples were tested in the above assay, and all were found to possess a K_i value for displacement of [^3H]-spiperone from the human dopamine D_4 receptor subtype of below 2.5 μM .

The following compounds of the present invention are preferred:

- 30 6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
2-[[4-(4-Chlorophenyl)-1-piperazinyl]methyl]-8-methylimidazo[1,2-a]pyridine;
2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl]methyl]-8-methylimidazo[1,2-a]pyridine monomaleic acid salt;
35 6-Bromo-2-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
and

WO 96/25414

PCT/US96/01114

2-[[4-(4-Chlorophenyl)-1-piperazinyl]methyl]imidazol[1,2-a]pyridine.

The following compound of the present invention is most preferred:

6-Bromo-2-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

5 When the term imidazo[1,2-a]pyridines (I) is used it includes a particular compound, enantiomers thereof and racemic forms thereof where such compounds exist and are pharmacologically useful as described herein.

All temperatures are in degrees Centigrade.

10 TLC refers to thin-layer chromatography. R_f is chromatographic movement relative to solvent front.

HPLC refers to high pressure liquid chromatography.

THF refers to tetrahydrofuran.

DMSO refers to dimethylsulfoxide.

DMF refers to dimethylformamide.

15 Saline refers to an aqueous saturated sodium chloride solution.

IR refers to infrared spectroscopy. Only the most intense absorptions are reported.

NMR refers to nuclear (proton) magnetic resonance spectroscopy. Chemical shifts are reported in ppm (δ) downfield from tetramethylsilane. ^1H -NMR is proton
20 nuclear magnetic resonance spectrum. ^{13}C -NMR is carbon nuclear magnetic resonance spectrum.

TMS refers to trimethylsilyl.

$-\phi$ refers to phenyl (C_6H_5).

25 $[\alpha]_D^{25}$ refers to the angle of rotation of plane polarized light (specific optical rotation) at 25° with the sodium D line (5893A).

MS refers to mass spectrometry expressed as m/e or mass/charge unit. $[\text{M} + \text{H}]^+$ refers to the positive ion of a parent plus a hydrogen atom. EI refers to electron impact. CI refers to chemical ionization. FAB refers to fast atom bombardment. HRMS is high-resolution mass spectroscopy.

30 Ether refers to diethyl ether.

Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and
35 bioavailability.

When solvent pairs are used, the ratios of solvents used are volume/volume

WO 96/25414

PCT/US96/01114

(v/v).

When the solubility of a solid in a solvent is used the ratio of the solid to the solvent is weight/volume (wt/v).

THF is distilled from sodium or potassium metal and benzophenone prior to

5 use. Other solvents are used as obtained from commercial suppliers.

mp are melting points and are uncorrected.

AlCl_3 is aluminum chloride.

Anal. is analytical data.

CDCl_3 is deuterio-chloroform.

10 CD_3OD is deuterio-methanol.

CH_2Cl_2 is methylene chloride.

cm^{-1} is reciprocal centimeters.

CuBr_2 is cupric bromide.

EtOAc is ethyl acetate.

15 Et_3Al is triethyl aluminum.

HCl is hydrochloric acid.

H_2O is water.

HOBT is 1-hydroxybenzotriazole hydrate.

KOH is potassium hydroxide.

20 M is molar (concentration).

MeOH is methanol.

Me_2S is dimethyl sulfide.

mg is milligram.

MgSO_4 is magnesium sulfate.

25 mL is milliliter.

mmHg is millimeter of mercury.

N is normal (concentration).

Na_2CO_3 is sodium carbonate.

Na_2SO_4 is sodium sulfate.

30 Pd/C is palladium on charcoal.

TFA is trifluoroacetic acid.

The chemical structural formula for the EXAMPLEs below are set forth in Chart L and correspond to the EXAMPLEs in the following manner. E-x is the chemical structural formula for EXAMPLE x. Even though the EXAMPLE may

35 have produced a particular salt form, the chemical structural formulas may identify the compound in its free (non-salt) form.

WO 96/25414

PCT/US96/01114

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as

5 merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques. Thus, the following Examples illustrate the present invention:

EXAMPLE 1 6-Chloro-2-[[4-(4-methoxyphenyl)-1-piperazinyl)methyl]-
10 imidazo[1,2-a]pyridine. Refer to Chart D.

Step 1. Ethyl 6-Chloroimidazo[1,2-a]pyridine-2-carboxylate

To 2-amino-5-chloropyridine (Aldrich; 2.19 g) in dimethoxyethane (Aldrich; 25 mL) is added ethyl 2-bromopyruvate (Aldrich; 2.37 mL). After stirring overnight, the solid is collected and washed with diethyl ether. The solid is dried under

15 reduced pressure at 45 °C and then is partitioned between dichloromethane and aqueous sodium bicarbonate. The organic phases are dried over sodium sulfate and concentrated to give 3.05 g of ethyl 6-chloroimidazo[1,2-a]pyridine-2-carboxylate. ¹H NMR (CDCl₃) δ 1.44, 4.46, 7.23, 7.64, 8.16, 8.21.

Step 2. 6-Chloroimidazo[1,2-a]pyridine-2-carboxylic acid

To ethyl 6-chloroimidazo[1,2-a]pyridine-2-carboxylate (0.54 g) in ethanol (5 mL) are added 1N NaOH (3.1 mL) and water and additional ethanol to aid in stirring. After one hour, ethanol is removed under reduced pressure and the residue is acidified with 2 N HCl until the pH reaches 4-6. The solid is collected and washed several times with water to give, after drying, 0.40 g of 6-chloroimidazo[1,2-

25 a]pyridine-2-carboxylic acid. ¹H NMR (DMSO-d₆) δ 7.40, 7.68, 8.44, 8.85

Step 3. 1-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)carbonyl]-4-(4-methoxy-
phenyl)piperazine

To 6-chloroimidazo[1,2-a]pyridine-2-carboxylic acid (0.170 g) and 1-(4-methoxyphenyl)piperazine (Aldrich; 0.165 g) in dichloromethane (4 mL) are added

30 diethyl cyanophosphonate (Aldrich; 0.157 mL) and triethylamine (0.144 mL), followed by DMF (2 mL). After stirring overnight, the mixture is quenched with aqueous sodium bicarbonate and then partitioned between dichloromethane and aqueous sodium bicarbonate. The organic layers are filtered through sodium sulfate and concentrated, and the residue is chromatographed on silica gel using

35 methanol/dichloromethane (2/98) to give 0.212 g of 1-[(6-chloroimidazo[1,2-a]pyridin-2-yl)carbonyl]-4-(4-methoxyphenyl)piperazine; mp 180-181 °C; IR (mineral oil) 1620,

WO 96/25414

PCT/US96/01114

1517, 1237, 1246, 1230 cm^{-1} . ^1H NMR (CDCl_3) δ 3.16, 3.78, 3.97, 4.47, 6.86, 6.94, 7.21, 7.56, 8.10, 8.20.

Step 4. 6-Chloro-2-[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine

5 To 1-[(6-chloroimidazo[1,2-a]pyridin-2-yl)carbonyl]-4-(4-methoxyphenyl)piperazine (0.182 g) in THF (6 mL) is added borane-methyl sulfide complex (Aldrich; 0.14 mL). Additional THF (4 mL) is added and the mixture is stirred overnight, after which it is quenched with the dropwise addition of methanol. The mixture is concentrated under reduced pressure and then acetone/6N HCl (10/1) is
10 added. The resulting mixture is stirred for 40 min and then concentrated under reduced pressure. The residue is partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are filtered through sodium sulfate, concentrated, and the residue chromatographed on silica gel using methanol/dichloromethane (2/98 to 4/96) to give 0.027 g of the title compound; mp
15 111-112 °C; IR (mineral oil) 1512, 1254, 1498, 1035, 830 cm^{-1} . ^1H NMR (CDCl_3) δ 2.74, 3.13, 3.76, 3.77, 6.82, 6.90, 7.12, 7.52, 7.54, 8.13.

EXAMPLE 2 4-[4-[(Imidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-benzenesulfonamide. Refer to Chart E.

Step 1. 2-(Chloromethyl)imidazo[1,2-a]pyridine

20 A mixture of 2-aminopyridine (Aldrich; 0.487 g), 1,3-dichloroacetone (Aldrich; 0.73 g), and dimethoxyethane (6 mL) is stirred at room temperature for 2.5 h and then at 60 °C for 30 min. Dimethoxyethane is then removed under reduced pressure and ethanol (10 mL) is added. The mixture is stirred at 80 °C for 20 min and then cooled and concentrated under reduced pressure. The residue is partitioned between
25 dichloromethane and aq. sodium bicarbonate and the organic layers are filtered through sodium sulfate and concentrated. Dichloromethane and ethyl acetate are added to the residue and the solids are removed by filtration. The filtrate is concentrated and the residue is chromatographed on silica gel using ethyl acetate/hexane (50/50) to give 0.495 g of 2-(chloromethyl)imidazo[1,2-a]pyridine; mp
30 >255 °C; ^1H NMR (CDCl_3) δ 4.78, 6.80, 7.19, 7.58, 7.62, 8.08.

Step 2. 4-(Piperazin-1-yl)benzenesulfonamide. Refer to Chart C.

A mixture of 4-fluorobenzenesulfonamide (6.95 g) and piperazine (17.1 g) in 30 mL of water is heated at 100 °C overnight. The solid is then collected, washed with water and toluene, and dried under reduced pressure to give 9.2 g of 4-
35 (piperazin-1-yl)benzenesulfonamide; mp 219-221 °C; ms m/z 241; IR (mineral oil) 1160, 822, 1332, 608, 1593, 1137 cm^{-1} . ^1H NMR ($\text{DMSO}-d_6$) δ 2.81, 3.17, 2.3, 7.01.

WO 96/25414

PCT/US96/01114

7.07, 7.61.

Step 3. 4-[4-[(Imidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-
benzenesulfonamide

A mixture of 2-(chloromethyl)imidazo[1,2-a]pyridine (0.495 g), 4-(piperazin-1-yl)benzenesulfonamide (0.717 g), triethylamine (0.456 mL), and ethylene glycol (6 mL) is stirred at 80 °C for 1.5 h. After cooling, water is added and the resulting solid is collected and washed with water and toluene. Chromatography on silica gel using methanol/dichloromethane (6/94) yields 0.69 g of the title compound; mp 238-242 °C; IR (mineral oil) 1150, 1152, 1331, 1308, 1508 cm⁻¹. ¹H NMR (DMSO-d₆) δ 2.61, 3.28, 3.66, 6.86, 7.02, 7.06, 7.20, 7.49, 7.61, 7.85, 8.50.

EXAMPLE 3 4-[4-[(Imidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-
benzamide. Refer to Chart E

Step 1. 4-(Piperazin-1-yl)benzamide. Refer to Chart C.

A mixture of piperazine (7.56 g) and 4-fluorobenzamide (2.44 g) in water (10 mL) is heated at reflux for 27 h. The mixture is then allowed to cool slightly and the solid is collected and washed with water and dichloromethane, followed by drying to give 3.24 g of 4-(piperazin-1-yl)benzamide; mp 238-243 °C; ms m/z 205; IR (mineral oil) 1609, 1255, 1665, 1389, 3149 cm⁻¹. ¹H NMR (DMSO-d₆) δ 2.59, 2.80, 3.14, 6.90, 7.02, 7.72, 7.73.

Step 2. 4-[4-[(Imidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide

Following the general procedure of Example 2, Step 3, and making noncritical variations, 2-(chloromethyl)imidazo[1,2-a]pyridine (Example 2, Step 1; 0.245 g), 4-(piperazin-1-yl)benzamide (0.302 g), diisopropylethylamine (Aldrich; 0.256 mL), and ethylene glycol (2 mL) gives 0.313 g of the title compound after chromatography (silica gel, methanol/dichloromethane, 8/92, as eluent) and crystallization from methanol/dichloromethane; mp 249-250 °C; IR (mineral oil) 1608, 1398, 1253, 1739, 3133, 756 cm⁻¹. ¹H NMR (CDCl₃) δ 2.74, 3.36, 3.78, 5.7, 6.78, 6.88, 7.16, 7.55, 7.58, 7.71, 8.09.

EXAMPLE 4 4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide. Refer to Chart E.

Step 1. 6-Chloro-2-(chloromethyl)imidazo[1,2-a]pyridine

A mixture of 5-chloro-2-aminopyridine (Aldrich; 10.07 g), 1,3-dichloroacetone (Aldrich; 10.22 g), and dimethoxyethane (Aldrich; 35 mL) is stirred overnight, after which time ethanol (20 mL) is added and the mixture is heated at 80 °C for 7 h. After cooling, the solvents are removed under reduced pressure and the residue is partitioned between dichloromethane and aq. sodium bicarbonate. The organic

WO 96/25414

PCT/US96/01114

layers are filtered through sodium sulfate, concentrated, and the residue chromatographed on silica gel using ethyl acetate/chloroform (5/95) to give 8.71 g of a white solid. Crystallization from dichloromethane/hexane gives 8.27 g of 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine in two crops; mp 123-124 °C; IR (mineral oil) 1073, 800, 701, 1339, 1499, 839 cm^{-1} . ^1H NMR (CDCl_3) δ 4.75, 7.17, 7.53, 7.60, 8.14.

Step 2. 4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide

Following the general procedure of Example 2, Step 3, and making noncritical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (0.500 g), 4-(piperazin-1-yl)benzamide (Example 3, Step 1; 0.536 g), triethylamine (0.477 g), and ethylene glycol (6 mL) give 0.40 g of the title compound after chromatography on silica gel using methanol/dichloromethane (8/92) and crystallization from methanol/dichloromethane; mp 240-241 °C; IR (mineral oil) 1612, 1646, 1331, 3359, 1501 cm^{-1} . ^1H NMR (DMSO_d6) δ 2.60, 3.25, 3.66, 6.92, 7.04, 7.25, 7.54, 7.72, 7.73, 7.84, 8.80.

EXAMPLE 5 4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzenesulfonamide. Refer to Chart E.

Following the general procedure of Example 2, Step 3, and making noncritical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.500 g), 4-(piperazin-1-yl)benzenesulfonamide (Example 2, Step 2; 0.630 g), triethylamine (0.477 g), and ethylene glycol (6 mL) give 0.40 g of the title compound after chromatography on silica gel using methanol/dichloromethane (8/92) and crystallization from methanol/dichloromethane; mp 255-256 °C; IR (mineral oil) 1153, 1327, 1322, 3306, 1106 cm^{-1} . ^1H NMR (DMSO_d6) δ 2.60, 3.29, 3.66, 7.01, 7.06, 7.25, 7.54, 7.60, 7.84, 8.80.

EXAMPLE 6 2-[[4-(4-Fluorophenyl)-1-piperazinyl)methyl]-7-methylimidazo[1,2-a]pyridine. Refer to Chart E.

Step 1. 2-(Chloromethyl)-7-methylimidazo[1,2-a]pyridine

A mixture of 2-amino-4-picoline (Aldrich; 5.00 g), 1,3-dichloroacetone (Aldrich; 5.89 g), and 1,2-dimethoxyethane (Aldrich; 44 mL) is stirred for 25 min at 53 °C. at which time ethanol (47.5 mL) is added. After stirring for 2.5 h at reflux, the mixture is concentrated under reduced pressure and the residue is partitioned between dichloromethane and saturated sodium bicarbonate and brine. The organic layers are dried over MgSO_4 and concentrated under reduced pressure. The crude material is chromatographed on silica gel using methanol/dichloromethane (1/99 to

WO 96/25414

PCT/US96/01114

2/98) to give, after crystallization from dichloromethane/hexane, 3.06 g of product. A portion of this material is dissolved in dichloromethane and refluxed with activated charcoal for 30 min. The activated charcoal is removed by filtration through a pad of diatomaceous earth and the filtrate is atmospherically concentrated, at which
5 time hexane is added. The resulting solids are filtered, washed with hexane, and vacuum dried to give 0.15 g of 2-(chloromethyl)-7-methylimidazo[1,2-*a*]pyridine: mp 250 °C (decomp); ms *m/z* 180, 182; IR (mineral oil) 774, 1649, 1504, 1252, 701 cm⁻¹; ¹H NMR (CDCl₃) δ 2.39, 4.75, 6.63, 7.32, 7.53, 7.95.

Step 2. 2-[[4-(4-Fluorophenyl)-1-piperazinyl]methyl]-7-methylimidazo[1,2-
10 a]pyridine

A mixture of 2-(chloromethyl)-7-methylimidazo[1,2-*a*]pyridine (0.302 g), 1-(4-fluorophenyl)piperazine (Aldrich; 0.315 g), triethylamine (Aldrich; 0.26 mL), and ethylene glycol (Mallinckrodt; 2 mL) is stirred for 2 h at 80-85 °C. Water (4 mL) is then added to the cooled mixture, which is then partitioned between
15 dichloromethane and aq. sodium bicarbonate. The combined organic layers are washed with brine, dried with MgSO₄, and concentrated under reduced pressure. The crude material is chromatographed on silica gel using methanol/dichloromethane/ammonium hydroxide (4/96/0.5). The appropriate fractions are combined and concentrated and the resulting solid is dissolved in ethyl
20 acetate/hexane/methanol. Activated charcoal is added and the slurry is refluxed for 30 min, at which time the activated charcoal is removed by filtration through a pad of diatomaceous earth. The filtrate is concentrated and the residue crystallized from ethyl acetate to give 0.135 g of the title compound; mp 127.5-128 °C; ms *m/z* 324; IR (mineral oil) 1506, 1226, 1239, 813, 1340 cm⁻¹; ¹H NMR (CDCl₃) δ 2.38, 2.74, 3.15,
25 3.75, 6.59, 6.89, 7.32, 7.46, 7.95.

EXAMPLE 7 4-[4-[(7-Methylimidazo[1,2-*a*]pyridin-2-yl)methyl]-1-piperazinyl]benzamide. Refer to Chart E.

A mixture of 2-(chloromethyl)-7-methylimidazo[1,2-*a*]pyridine (Example 6, Step 1; 0.300 g), 4-(piperazin-1-yl)benzamide (Example 3, Step 1; 0.357 g),
30 triethylamine (Aldrich; 0.26 mL), and ethylene glycol (2 mL) is stirred for 30 min at 80-85°C. Additional ethylene glycol (1 mL) is added and the mixture is stirred for another 1.5 h. Water (8 mL) is added to the cooled mixture and the resulting solid is collected and dried. This material is adsorbed to silica gel and chromatographed on silica gel using methanol/dichloromethane/ammonium hydroxide (8/92/0.5). The
35 appropriate fractions are combined and concentrated and the residue is crystallized from ethyl acetate/methanol to give 0.211 g of the title compound; mp 217-218 °C;

WO 96/25414

PCT/US96/01114

ms m/z 349; IR (mineral oil) 1608, 1662, 1239, 3393, 1520 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.39, 2.74, 3.35, 3.75, 6.60, 6.88, 7.32, 7.46, 7.70, 7.95.

EXAMPLE 8 1-[1-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one. Refer to Chart E.

5 A mixture of 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1: 0.186 g), 4-(2-keto-1-benzimidazolynyl)piperidine (Aldrich; 0.201 g), triethylamine (0.094 g), and dichloromethane (4 mL) is stirred at 45 °C for 20 h, after which time the mixture is cooled. Dichloromethane and aqueous sodium bicarbonate are added and the solids collected and dried. Additional material is
10 obtained by concentration of the organic layer. Crystallization from methanol/dichloromethane/hexane gives 0.123 g of the title compound; mp 210-211 (decomp)°C; IR (mineral oil) 1695, 1486, 1338, 736, 1074 cm^{-1} . ^1H NMR (DMSO-d_6) δ 1.63, 2.19, 2.38, 3.08, 3.66, 4.12, 6.96, 7.23, 7.54, 7.87, 8.80, 10.84.

EXAMPLE 9 2-[[4-(4-Fluorophenyl)-1-piperazinyl)methyl]-6-methyl-
15 imidazo[1,2-a]pyridine. Refer to Chart E.

Step 1. 2-(Chloromethyl)-6-methylimidazo[1,2-a]pyridine

A mixture of 2-amino-5-picoline (Aldrich; 5.028 g), 1,3-dichloroacetone (Aldrich; 5.893 g), and 1,2-dimethoxyethane (Aldrich; 43 mL) is stirred for 1 h at 55 °C, at which time ethanol (47 mL) is added and the mixture is stirred for 2.75 h at
20 reflux. The mixture is then concentrated under reduced pressure and partitioned between dichloromethane and saturated aq. sodium bicarbonate. The combined organic layers are washed with brine, dried with MgSO_4 , and concentrated under reduced pressure. The residue is chromatographed on silica gel using methanol/dichloromethane (1/99) and the appropriate fractions are combined and
25 concentrated to give, after crystallization from ethyl acetate, 0.411 g of 2-(chloromethyl)-6-methylimidazo[1,2-a]pyridine. Methanol is added to the filtrate, which is then concentrated to a reduced volume. The addition of hexane gives an additional 1.50 g of 2-(chloromethyl)-6-methylimidazo[1,2-a]pyridine in two crops; mp 88-89.25 °C; ms m/z 180; IR (mineral oil) 796, 705, 699, 1343, 1510 cm^{-1} ; ^1H
30 NMR (CDCl_3) δ 2.32, 4.76, 7.03, 7.47, 7.53, 7.86.

Step 2. 2-[[4-(4-Fluorophenyl)-1-piperazinyl)methyl]-6-methylimidazo[1,2-a]pyridine

A mixture of 2-(chloromethyl)-6-methylimidazo[1,2-a]pyridine (0.302 g), 1-(4-fluorophenyl)piperazine (Aldrich; 0.319 g), triethylamine (Aldrich; 0.26 mL), and
35 ethylene glycol (2 mL) is stirred for 2.25 h at 80-85 °C. The cooled mixture is then poured into saturated aq. sodium bicarbonate and extracted several times with

WO 96/25414

PCT/US96/01114

dichloromethane. The combined organic layers are washed with brine, dried with MgSO_4 , and concentrated under reduced pressure. The crude material is chromatographed on silica gel using methanol/dichloromethane/ammonium hydroxide (4/96/0.25) and crystallized from ethyl acetate/hexane to give 0.300 g of the title compound; mp 112-112.5 °C; ms m/z 324; IR (mineral oil) 1511, 804, 1234, 1246, 1345 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.31, 2.74, 3.15, 3.76, 6.90, 7.46, 7.86.

EXAMPLE 10 4-[4-[(6-Methylimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide. Refer to Chart E.

Following the general procedure of Example 2. Step 3, and making non-critical variations, 2-(chloromethyl)-6-methylimidazo[1,2-a]pyridine (Example 9, Step 1; 0.3017 g) and 4-(piperazin-1-yl)benzamide (Example 3, Step 1; 0.3633 g) give, after chromatography on silica gel using methanol/dichloromethane/ammonium hydroxide (8/92/0.25), 0.2583 g of the title compound after crystallization from methanol/dichloromethane; mp 227-228.5 °C; MS m/z 349; IR (mineral oil) 1611, 1645, 1343, 1451, 3380 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.31, 2.73, 3.35, 3.75, 6.87, 6.99, 7.46, 7.48, 7.71, 7.87.

EXAMPLE 11 6-Chloro-2-[[4-(4-fluorophenyl)-1-piperazinyl)methyl]-imidazo[1,2-a]pyridine. Refer to Chart E.

A mixture of 2-(chloromethyl)-6-chloroimidazo[1,2-a]pyridine (Example 4, Step 1; 0.50 g), 1-(4-fluorophenyl)piperazine (Aldrich; 0.471 g), triethylamine (0.277 g), and ethylene glycol (2 mL) is stirred at 80 °C for 1.3 h. After cooling, the mixture is partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and the filtrate is concentrated under reduced pressure. The residue is chromatographed on silica gel using methanol/dichloromethane (2/98) and the appropriate fractions are combined and concentrated. The resulting material is crystallized from dichloromethane/hexane to give 0.66 g of the title compound; mp 129.5-131 °C; MS m/z at 344; IR (mineral oil) 1511, 1236, 1330, 1325, 825 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.74, 3.15, 6.86-6.98, 7.13, 7.52, 7.54, 8.14.

EXAMPLE 12 6-Chloro-2-[[4-(2-chlorophenyl)-1-piperazinyl)methyl]-imidazo[1,2-a]pyridine. Refer to Chart E.

Following the general procedure of Example 11 and making noncritical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4. Step 1; 0.289 g) and 1-(2-chlorophenyl)piperazine monohydrochloride (Aldrich; 0.381 g) give, after crystallization from ethyl acetate/hexane, 0.2423 g of the title compound; mp 123-123.5 °C; MS m/z 360; IR (mineral oil) 1325, 1475, 1039, 2818, 2810 cm^{-1} ; ^1H NMR

WO 96/25414

PCT/US96/01114

(CDCl₃) δ 2.77, 3.12, 3.79, 6.96, 7.04, 7.12, 7.21, 7.34, 7.52, 8.14.

EXAMPLE 13 2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile. Refer to Chart E.

Following the general procedure of Example 11 and making noncritical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.3373 g) and 1-(2-cyanophenyl)piperazine (Emka-Chemie; 0.347 g) give, after crystallization from dichloromethane/ethyl acetate, 0.309 g of the title compound; mp 167-169 °C; MS *m/z* 351, 353; IR (mineral oil) 1326, 1448, 809, 1484, 1073 cm⁻¹; ¹H NMR (CDCl₃) δ 2.79, 3.27, 3.79, 6.99, 7.12, 7.52, 8.14.

EXAMPLE 14 1-[1-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-4-piperidinyl]-1,3-dihydro-3-methyl-2H-benzimidazol-2-one. Refer to Chart K.

Sodium hydride (60% in oil; 0.0071 g) is washed once with hexane and THF is added to the remaining solid. To this mixture is added 1-[1-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one (Example 8; 0.052 g), followed by DMF (1 mL). After stirring for 60 min, methyl iodide (0.012 mL) is added. The mixture is stirred an additional 40 min, at which time the solvents are removed under reduced pressure and the residue is partitioned between dichloromethane and brine. The organic layers are dried over sodium sulfate and concentrated. The residue is chromatographed on silica gel using methanol/dichloromethane (4/96) and the appropriate fractions are combined and concentrated to give 0.0327 g of the title compound as a white solid; ms *m/z* 395; IR (mineral oil) 1700, 1498, 1340, 1714, 1074 cm⁻¹.

EXAMPLE 15 6-Bromo-2-[[4-(4-fluorophenyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine. Refer to Chart E.

Step 1. 6-Bromo-2-(chloromethyl)imidazo[1,2-a]pyridine

A mixture of 2-amino-5-bromopyridine (Aldrich; 2.88 g), 1,3-dichloroacetone (Aldrich; 2.74 g), and dimethoxyethane (30 mL) is stirred at room temperature overnight, after which time the resulting solid is collected and washed with several milliliters of dimethoxyethane. The solid is then dissolved in ethanol and stirred at 80 °C for 5 h. After cooling, the solvent is removed under reduced pressure and the residue is partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated to give 2.43 g of material. Crystallization from dichloromethane/hexane gives 2.26 g of 6-bromo-2-(chloromethyl)imidazo[1,2-a]pyridine; mp 125-126 °C; MS *m/z* 244, 246; IR (mineral oil) 798, 1497, 688, 1335, 1266 cm⁻¹. ¹H NMR (CDCl₃) δ 4.75, 7.26, 7.48, 7.60, 8.24.

Step 2. 6-Bromo-2-[[4-(4-fluorophenyl)-1-piperazinyl)methyl]imidazo[1,2-

WO 96/25414

PCT/US96/01114

a]pyridine

Following the general procedure of Example 11 and making noncritical variations, 6-bromo-2-(chloromethyl)imidazo[1,2-a]pyridine (0.253 g), 1-(4-fluorophenyl)piperazine (Aldrich; 0.186 g), triethylamine (Aldrich; 0.104 g), and ethylene glycol (2 mL) give 0.249 g of the title compound after chromatography (silica gel, methanol/dichloromethane, 4/96) and crystallization from dichloromethane/hexane; mp 110-112 °C; MS m/z 388, 390; IR (mineral oil) 1511, 1234, 1219, 1448, 1326 cm⁻¹. ¹H NMR (CDCl₃) δ 2.74, 3.16, 3.77, 6.87-6.98, 7.21, 7.48, 7.53, 8.24.

10 EXAMPLE 16 4-[4-[(6-Bromoimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide. Refer to Chart E.

Following the general procedure of Example 2, Step 3, and making noncritical variations, 6-bromo-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 15, Step 1; 0.252 g), 4-(piperazin-1-yl)benzamide (Example 3, Step 1; 0.211 g), triethylamine (0.104 g), and ethylene glycol (2 mL) give 0.206 g of the title compound after crystallization from methanol/dichloromethane/hexane; mp 238-239 °C; MS m/z 413, 415; IR (mineral oil) 1612, 1656, 3379, 1331, 1240 cm⁻¹. ¹H NMR (DMSO-d₆) δ 2.60, 3.25, 3.66, 6.92, 7.04, 7.32, 7.49, 7.71, 7.73, 7.83, 8.87.

15 EXAMPLE 17 6-Chloro-2-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-imidazo[1,2-a]pyridine. Refer to Chart E.

Following the general procedure of Example 11 and making noncritical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.354 g), 1-(4-chlorophenyl)piperazine dihydrochloride (Aldrich; 0.475 g), triethylamine (0.552 g), and ethylene glycol (2 mL) give 0.363 g of the title compound after chromatography (silica gel, methanol/dichloromethane, 4/96) and crystallization from dichloromethane/hexane; mp 145-146 °C; MS m/z 360; IR (mineral oil) 823, 1500, 1496, 1225, 814 cm⁻¹. ¹H NMR (CDCl₃) δ 2.72, 3.19, 3.76, 6.83, 7.13, 7.19, 7.52, 7.53, 8.14.

20 EXAMPLE 18 6-Chloro-2-[[4-(3-chlorophenyl)-1-piperazinyl]methyl]-imidazo[1,2-a]pyridine. Refer to Chart E.

Following the general procedure of Example 11 and making noncritical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.354 g), 1-(3-chlorophenyl)piperazine dihydrochloride (Aldrich; 0.475 g), triethylamine (0.552 g), and ethylene glycol (2 mL) give 0.372 g of the title compound after chromatography (silica gel, methanol/dichloromethane, 4/96) and crystallization from dichloromethane/hexane; mp 148-149 °C; MS m/z 360; IR (mineral oil) 1594, 1340,

WO 96/25414

PCT/US96/01114

1073, 1218, 1502 cm^{-1} . ^1H NMR (CDCl_3) δ 2.71, 3.23, 3.76, 6.79, 6.86, 7.14, 7.52, 7.53, 8.14.

EXAMPLE 19 6,8-Dichloro-2-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-imidazo[1,2-a]pyridine. Refer to Chart E.

5 Step 1. 6,8-Dichloro-2-(chloromethyl)imidazo[1,2-a]pyridine

A mixture of 2-amino-3,5-dichloropyridine (Aldrich; 5.12 g), 1,3-dichloroacetone (Aldrich; 4.68 g), and dimethoxyethane (28 mL) is stirred overnight at room temperature. Ethanol (28 mL) is then added and the mixture is refluxed for 7.5 h and then stirred overnight at room temperature. The mixture is then refluxed
10 for an additional 24 h and is then concentrated under reduced pressure and partitioned between saturated aq. sodium bicarbonate and dichloromethane. The combined organic layers are washed with brine, dried with MgSO_4 , and concentrated under reduced pressure. The residue is adsorbed to silica gel and chromatographed on silica gel using ethyl acetate/chloroform (10/90), followed by a second
15 chromatography of the combined product fractions using methanol/dichloromethane (2/98), to give 2.22 g of 6,8-dichloro-2-(chloromethyl)imidazo[1,2-a]pyridine in three crops after crystallization from methanol/dichloromethane; mp 162-163 $^\circ\text{C}$; MS m/z 234, 236, 238; IR (mineral oil) 994, 808, 861, 1522, 3056 cm^{-1} ; ^1H NMR (CDCl_3) δ 4.79, 7.69, 8.10.

20 Step 2. 6,8-Dichloro-2-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine

A mixture of 6,8-dichloro-2-(chloromethyl)imidazo[1,2-a]pyridine (0.3064 g), 1-(4-fluorophenyl)piperazine (Aldrich; 0.266 g), triethylamine (Aldrich; 0.21 mL), and ethylene glycol (2 mL) is stirred for 1 h at 80-85 $^\circ\text{C}$. After cooling, the mixture is
25 partitioned between water and dichloromethane and the organic layers are washed with brine and dried over MgSO_4 . After concentration under reduced pressure, the residue is chromatographed on silica gel using methanol/dichloromethane (4/96) and the appropriate fractions are combined and concentrated and the residue is crystallized from ethyl acetate/hexane to give 0.3098 g of the title compound; mp
30 126.5-127.5 $^\circ\text{C}$; MS m/z 378, 380; IR (mineral oil) 1510, 1215, 1335, 826, 1224 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.75, 3.15, 3.83, 6.87, 6.96, 7.26, 7.62, 8.09.

EXAMPLE 20 2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide. Refer to Chart E.

Step 1. 2-(Piperazin-1-yl)benzamide. Refer to Chart C.

35 A mixture of 2-fluorobenzamide (Aldrich; 9.83 g), piperazine (Aldrich; 30.5 g), and water (135 mL) is heated at 100 $^\circ\text{C}$ for 26 h and at room temperature for an

WO 96/25414

PCT/US96/01114

additional 3 days. About two-thirds of the water is then distilled off and the mixture is heated again at 100 °C overnight. After cooling, the resulting solid is collected, washed with water and toluene, and dried under reduced pressure to give 2.42 g of 2-(piperaziny-1-yl)benzamide; mp 128-134 °C; ms *m/z* 205; IR (mineral oil) 3322, 3274, 1595, 1665, 2815 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.36, 3.02, 5.91, 7.23, 7.48, 8.16, 9.55.

Step 2. 2-[4-[(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)methyl]-1-piperaziny]benzamide

Following the general procedure of Example 11 and making non-critical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-*a*]pyridine (Example 4, Step 1; 0.306 g) and 2-(piperazin-1-yl)benzamide (0.336 g) are converted to 0.236 g of the title compound after chromatography on silica gel using methanol/dichloromethane (8/92) and crystallization from ethyl acetate/dichloromethane. A portion of this material was recrystallized from ethyl acetate/methanol/hexane; mp 178-179 °C; ms *m/z* 369; IR (mineral oil) 1663, 3289, 1325, 1448, 796 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.75, 3.08, 3.78, 5.76, 7.13, 7.23, 7.46, 7.52, 7.53, 8.14, 8.17, 9.57.

EXAMPLE 21 2-[4-[(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)methyl]-1-piperaziny]-5-fluorobenzonitrile. Refer to Chart E.

Step 1. 5-Fluoro-2-(piperazin-1-yl)benzonitrile. Refer to Chart C.

A mixture of piperazine (Aldrich; 1.28 g), 2,5-difluorobenzonitrile (Lancaster; 0.422 g), and DMF (4 mL) is stirred at 80 °C for 1.5 h, after which the mixture is cooled and partitioned between dichloromethane, water, and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate, concentrated, and the residue is crystallized from dichloromethane/ethyl ether/hexane to give 0.282 g of 5-fluoro-2-(piperazin-1-yl)benzonitrile; mp 83-83.5 °C; ^1H NMR (CDCl_3) δ 3.10, 7.00, 7.21, 7.27.

Step 2. 2-[4-[(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)methyl]-1-piperaziny]-5-fluorobenzonitrile

Following the general procedure of Example 11 and making noncritical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-*a*]pyridine (Example 4, Step 1; 0.199 g), 5-fluoro-2-(piperazin-1-yl)benzonitrile (0.203 g), triethylamine (0.110 g), and ethylene glycol (2 mL) give 0.218 g of the title compound after chromatography (silica gel, methanol/dichloromethane, 4/96) and crystallization from dichloromethane/hexane; mp 179-180 °C; MS *m/z* 369; IR (mineral oil) 1494, 1329, 808, 1452, 1072 cm^{-1} . ^1H NMR (CDCl_3) δ 2.78, 3.20, 3.78, 6.99, 7.13, 7.19, 7.26, 7.51, 7.52, 8.14.

EXAMPLE 22 4-[4-[(6,8-Dichloroimidazo[1,2-*a*]pyridin-2-yl)methyl]-1-

WO 96/25414

PCT/US96/01114

piperazinyl]benzamide. Refer to Chart E.

A mixture of 6,8-dichloro-2-(chloromethyl)imidazo[1,2-*a*]pyridine (Example 19, Step 1; 0.301 g), 4-(piperazin-1-yl)benzamide (Example 3, Step 1; 0.2916 g), triethylamine (Aldrich; 0.21 mL), and ethylene glycol (2 mL) is stirred for 1 h at 80-
5 85 °C. The mixture is then allowed to cool and water is added. The solids are collected, washed with water and hexane, and dried under reduced pressure. The solid is then adsorbed onto silica gel and chromatographed using methanol/dichloromethane (8/92). The appropriate fractions are combined and concentrated and the residue is crystallized from dichloromethane/methanol to give
10 0.2938 g of the title compound; mp 234-235 °C; MS *m/z* 403,405; IR (mineral oil) 1606, 1668, 1392, 1522, 1241 cm⁻¹; ¹H NMR (CDCl₃) δ 2.74, 3.35, 3.83, 6.89, 7.27, 7.63, 7.72, 8.10.

EXAMPLE 23 6-Bromo-2-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-imidazo[1,2-*a*]pyridine. Refer to Chart E.

15 A mixture of 6-bromo-2-(chloromethyl)imidazo[1,2-*a*]pyridine (Example 15, Step 1; 0.3042 g), 1-(4-chlorophenyl)piperazine dihydrochloride (Aldrich; 0.3708 g), triethylamine (Aldrich; 0.55 mL), and ethylene glycol (5.6 mL) is stirred for 1 h at 80 °C. After cooling, the mixture is partitioned between water and dichloromethane. The combined organic layers are washed with brine, dried with MgSO₄, and
20 concentrated under reduced pressure. The residue is chromatographed on silica gel using methanol/dichloromethane (4/96) to give, after crystallization from ethyl acetate/methanol/dichloromethane, 0.1756 g of the title compound; mp 154-155 °C; MS *m/z* 404, 406, 408; IR (mineral oil) 1495, 1500, 1224, 823, 812 cm⁻¹; ¹H NMR (CDCl₃) δ 2.72, 3.19, 3.76, 6.83, 7.20, 7.22, 7.47, 7.52, 8.24.

25 EXAMPLE 24 8-Chloro-2-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-6-trifluoromethylimidazo[1,2-*a*]pyridine. Refer to Chart E.

Step 1. 8-Chloro-2-(chloromethyl)-6-trifluoromethylimidazo[1,2-*a*]pyridine

A mixture of 2-amino-3-chloro-5-trifluoromethylpyridine (Aldrich; 5.1274 g), 1,3-dichloroacetone (Aldrich; 3.9523 g), and dimethoxyethane (23.5 mL) is stirred
30 overnight at room temperature. The mixture is then stirred at 50-55 °C for 4.5 h and again overnight at room temperature, at which time the mixture is concentrated under reduced pressure. Ethanol is added and the mixture is stirred at reflux for 4 h. After stirring overnight at room temperature, the mixture is again stirred at reflux for several hours. After cooling, the solvent is removed under reduced
35 pressure. The residue is partitioned between saturated sodium bicarbonate and dichloromethane. The combined organic layers are dried with MgSO₄, concentrated

WO 96/25414

PCT/US96/01114

under reduced pressure, and the residue is chromatographed on silica gel using methanol/dichloromethane (1/99). The appropriate fractions are combined and concentrated and the residue is crystallized from ethyl acetate/hexane to give 1.86 g of 8-chloro-2-(chloromethyl)-6-trifluoromethylimidazo[1,2-*a*]pyridine; mp 75-77 °C;

- 5 MS *m/z* 268, 270; IR (mineral oil) 1136, 1316, 1168, 869, 738 cm⁻¹; ¹H NMR (CDCl₃) δ 4.81, 7.45, 7.82, 8.43.

Step 2. 8-Chloro-2-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-6-trifluoromethylimidazo[1,2-*a*]pyridine

- A mixture of 8-chloro-2-(chloromethyl)-6-trifluoromethylimidazo[1,2-*a*]pyridine (0.341 g), 1-(4-fluorophenyl)piperazine (Aldrich; 0.264 g), triethylamine (Aldrich; 0.21 mL), and ethylene glycol (2 mL) is stirred for 2.25 h at 80-85 °C. After cooling, the mixture is partitioned between water and dichloromethane and the combined inorganic layers are washed with brine, dried with MgSO₄, and concentrated under reduced pressure. The residue is chromatographed on silica gel using methanol/dichloromethane (2/98) and the appropriate fractions combined, concentrated, and crystallized from ether/hexane to give 0.339 g of the title compound; mp 91-97 °C; MS *m/z* 412, 414; IR (mineral oil) 1322, 1161, 1153, 1512, 1171 cm⁻¹; ¹H NMR (CDCl₃) δ 2.76, 3.15, 3.87, 6.88, 6.96, 7.41, 7.75, 8.41.

- EXAMPLE 25 6-Chloro-2-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]-imidazo[1,2-*a*]pyridine. Refer to Chart E.

- Following the general procedure of Example 11 and making non-critical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-*a*]pyridine (Example 4, Step 1; 0.294 g) and 1-(2-fluorophenyl)piperazine hydrochloride (Aldrich; 0.366 g) are converted to 0.268 g of the title compound after chromatography on silica gel using methanol/dichloromethane (6/94) and crystallization from ethyl acetate/hexane; mp 107-108 °C; MS *m/z* 344, 346; IR (mineral oil) 1501, 1221, 752, 1335, 927 cm⁻¹; ¹H NMR (CDCl₃) δ 2.76, 3.13, 3.78, 6.95, 7.03, 7.12, 7.52, 8.14.

EXAMPLE 26 6-Chloro-2-[(4-phenyl-1-piperazinyl)methyl]imidazo[1,2-*a*]pyridine. Refer to Chart E.

- Following the general procedure of Example 11 and making non-critical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-*a*]pyridine (Example 4, Step 1; 0.296 g) and 1-phenylpiperazine hydrochloride (Aldrich; 0.333 g) are converted to 0.279 g of the title compound after chromatography on silica gel and crystallization from dichloromethane/ethyl ether/hexane; mp 128.5-130.5 °C; MS *m/z* 326, 328; IR (mineral oil) 1217, 1073, 1501, 921, 1600 cm⁻¹; ¹H NMR (CDCl₃) δ 2.74, 3.24, 3.77, 6.85, 6.92, 7.12, 7.26, 7.52, 8.13.

WO 96/25414

PCT/US96/01114

EXAMPLE 27 4-[4-[(8-Chloro-6-trifluoromethylimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide. Refer to Chart E.

Following the general procedure of Ex. 22 and making non-critical variations, 8-chloro-2-(chloromethyl)-6-trifluoromethylimidazo[1,2-a]pyridine (Example 24, Step 1; 0.347 g), 4-(piperazin-1-yl)benzamide (Example 3, Step 1; 0.293 g), triethylamine (0.21 mL) and ethylene glycol (2 mL) give 0.216 g of the title compound after crystallization from methanol/ethyl acetate; mp 205-206 °C; m/s m/z 437, 439; IR (mineral oil) 1142, 1644, 1616, 1610, 1321 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.74, 3.35, 3.86, 6.89, 7.42, 7.72, 7.75, 8.42.

10 EXAMPLE 28 6-Chloro-2-[[4-(3,4-dichlorophenyl)-1-piperazinyl]-methyl]imidazo[1,2-a]pyridine. Refer to Chart E.

Following the general procedure of Example 11 and making non-critical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.493 g) and 1-(3,4-dichlorophenyl)piperazine (Aldrich; 0.636 g) are converted to 0.404 g of the title compound after chromatography on silica gel and crystallization from ethyl ether/hexane; mp 122.5-123.5 °C; MS m/z 394; IR (mineral oil) 1339, 1488, 804, 1072, 2807 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.72, 3.21, 3.77, 6.72, 6.94, 7.13, 7.26, 7.52, 8.14.

20 EXAMPLE 29 3-Chloro-4-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile. Refer to Chart E.

Step 1. 3-Chloro-4-(piperazin-1-yl)benzonitrile. Refer to Chart C.

A mixture of 3,4-dichlorobenzonitrile (Lancaster; 3.003 g), piperazine (Aldrich; 7.485 g), and DMF (10 mL) is stirred for 2.5 h at 100 °C. After cooling, DMF is removed under reduced pressure and the residue is partitioned between dichloromethane and saturated aq. sodium bicarbonate. The organic layers are dried with MgSO_4 and concentrated under reduced pressure. The residue is chromatographed on silica gel using methanol/dichloromethane (8/92) to give 1.3785 g of 3-chloro-4-(piperazin-1-yl)benzonitrile; mp 85-87 °C; MS m/z 221, 223; IR (mineral oil) 2225, 3338, 1451, 826, 1236, 1594 cm^{-1} ; ^1H NMR (CDCl_3) δ 3.09, 7.03, 7.51, 7.62.

30 Step 2. 3-Chloro-4-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile

A mixture of 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.140 g), 3-chloro-4-(piperazin-1-yl)benzonitrile (0.155 g), triethylamine (0.078 g), and THF (2.5 mL) is heated at reflux for 5.5 h and then stirred overnight at room temperature. A few drops of triethylamine are then added and the mixture

WO 96/25414

PCT/US96/01114

is stirred an additional 4 h at reflux. After cooling, the mixture is concentrated and the residue is partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated. Chromatography of the residue on silica gel using methanol/dichloromethane (4/96) gives 0.238 g of the title compound. A portion of the material is recrystallized from ethyl acetate/ethyl ether/hexane; mp 137-138 °C; MS m/z 385, 387; IR (mineral oil) 1501, 2225, 1130, 1342, 1490 cm⁻¹. ¹H NMR (CDCl₃) δ 2.77, 3.21, 3.79, 7.03, 7.14, 7.47-7.54, 7.61, 8.14.

EXAMPLE 30 3-Chloro-4-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide. Refer to Chart F.

A mixture of 3-chloro-4-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile (Example 29; 0.122 g), NaOH (0.063 g), 30% hydrogen peroxide (2 drops), and tert-butanol (2 mL) is stirred at 80 °C for 4 h, after which it is cooled and concentrated under reduced pressure. The residue is partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated. The solids remaining suspended in the aqueous layer are collected, washed with water, dried under reduced pressure, and combined with the solids obtained from concentration of the organic layers. The solids are taken up in dichloromethane and methanol with warming and filtered through a cotton plug to remove insolubles. The filtrate is then concentrated and the residue is crystallized from dichloromethane/hexane to give 0.0745 g of the title compound; mp 254-256 °C; MS m/z 403, 405; IR (mineral oil) 1413, 1235, 1597, 800, 1328 cm⁻¹. ¹H NMR (DMSO-d₆) δ 2.64, 3.05, 3.69, 7.17, 7.25, 7.37, 7.55, 7.79, 7.84, 7.89, 7.96, 8.80.

EXAMPLE 31 6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]-methyl]imidazo[1,2-a]pyridine. Refer to Chart E.

Step 1. 1-(2,4-Dichlorophenyl)piperazine

A mixture of 1,3-dichloro-4-fluorobenzene (Aldrich; 4.21 g), piperazine (Aldrich; 11.0 g), and N,N-dimethylacetamide (Aldrich; 15 mL) is heated at 165 °C for 6.5 h. After cooling, the mixture is partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated under reduced pressure to give 4.48 g of 1-(2,4-dichlorophenyl)piperazine. ¹H NMR (CDCl₃) δ 3.00, 3.06, 6.96, 7.19, 7.36.

Step 2. 6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine

A mixture of 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4.

WO 96/25414

PCT/US96/01114

Step 1; 0.374 g), 1-(2,4-dichlorophenyl)piperazine (0.430 g), triethylamine (0.19 g), and ethylene glycol (2 mL) is stirred for 2 h at 80 °C. after which an additional 0.0374 g of 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine is added. After stirring for another 60 min, the mixture is cooled and partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate, concentrated, and chromatographed on silica gel using methanol/dichloromethane (4/96) to give 0.606 g of material. Crystallization from dichloromethane/hexane gives 0.518 g of the title compound; mp 136.5-137.5 °C; MS m/z 394, 396; IR (mineral oil) 1479, 1342, 2808, 1454, 1072 cm⁻¹. ¹H NMR (CDCl₃) δ 2.78, 3.09, 3.80, 6.96, 7.11-7.20, 7.35, 7.52, 7.55, 8.14.

The maleic acid salt is prepared by dissolving 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine (0.161 g) in methanol/dichloromethane and adding a solution of maleic acid (0.0472 g) in methanol. After five min, the mixture is concentrated under reduced pressure. Ethyl acetate is added to the residue, followed by hexane and dichloromethane. The resulting crystals are collected and dried to give 0.192 g of the maleic acid salt of 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine; mp 149-150 °C.

In a similar manner, the methanesulfonic acid salt is prepared from 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine (0.1006 g) and methanesulfonic acid (0.0244 g), with crystallization from ethyl acetate, to give 0.115 g of 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine methanesulfonate as a hygroscopic material.

In a similar manner, the sulfate salt is prepared from 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine (0.126 g) and concentrated sulfuric acid (0.0312 g), with crystallization from methanol/dichloromethane/hexane to give 0.129 g of the sulfate salt of 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine; mp: sharp transition at 170.5 °C and then further gradual melting to about 210 °C.

The dihydrochloride salt is prepared from 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine (0.055 g) and a solution of hydrogen chloride in methanol. After allowing the mixture to stand for several minutes, the solvent is removed under reduced pressure and the residue is crystallized from ethyl acetate to give 0.053 g of 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine dihydrochloride; mp 243-253 °C.

The fumaric acid salt is prepared by adding fumaric acid (0.0399 g) to a

WO 96/25414

PCT/US96/01114

solution of 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine (0.136 g) in dichloromethane. Methanol is added to the mixture and after several minutes the solvents are removed under reduced pressure. Ethyl acetate is added to the residue and upon warming, crystals form to give 0.128 g of the fumaric acid salt of 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine after collection and drying; mp 117-119 °C (shrinkage).

In a similar manner, the sulfamic acid salt is prepared from 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine (0.125 g) and sulfamic acid (0.0307 g), with crystallization from methanol/ethyl acetate, to give 0.145 g of 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine sulfamic acid salt; mp 134-137 °C.

EXAMPLE 32 5-Chloro-2-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile. Refer to Chart E.

Step 1. 5-Chloro-2-(piperazin-1-yl)benzonitrile. Refer to Chart C.

A mixture of 2,5-dichlorobenzonitrile (Lancaster; 2.994 g), piperazine (Aldrich; 7.616 g), and DMF (10 mL) is stirred for 4.5 h at 100 °C. After cooling, the DMF is removed under reduced pressure and the residue is partitioned between dichloromethane and saturated aq. sodium bicarbonate. The organic layers are dried with MgSO₄ and concentrated under reduced pressure. The residue is chromatographed on silica gel using methanol/dichloromethane (8/92) and the appropriate fractions are combined and concentrated to give 0.79 g of 5-chloro-2-(piperazin-1-yl)benzonitrile; MS *m/z* 221; IR (mineral oil) 1489, 802, 829, 2223, 845 cm⁻¹; ¹H NMR (CDCl₃) δ 3.09, 3.18, 6.94, 7.43, 7.52.

Step 2. 5-Chloro-2-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile

Following the general procedure of Example 11 and making non-critical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.292 g) and 5-chloro-2-(piperazin-1-yl)benzonitrile (0.385 g) are converted to 0.349 g of the title compound after chromatography on silica gel and crystallization from ethyl ether/dichloromethane/hexane. mp 191-191.5 °C; MS *m/z* 385, 387; IR (mineral oil) 1486, 1330, 806, 1495, 826 cm⁻¹; ¹H NMR (CDCl₃) δ 2.77, 3.24, 3.78, 6.93, 7.12, 7.42, 7.51, 8.14.

EXAMPLE 33 6-Chloro-2-[[4-[5-(trifluoromethyl)pyridin-2-yl]-1-piperazinyl]methyl]imidazo[1,2-a]pyridine. Refer to Chart E.

Step 1. 1-(5-Trifluoromethylpyridin-2-yl)piperazine. Refer to Chart C.

A mixture of 2-chloro-5-trifluoromethylpyridine (Aldrich; 2.296 g), piperazine

WO 96/25414

PCT/US96/01114

(5.45 g), and water is heated at 100 °C for 16 h. After cooling, the mixture is partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated. The residue is chromatographed on silica gel using methanol/dichloromethane (8/92) with about 5 0.5% ammonium hydroxide present, to give 2.20 g of 1-(5-trifluoromethylpyridin-2-yl)piperazine; mp 45-47 °C; IR (mineral oil) 1127, 1323, 1319, 1118, 1614 cm⁻¹; ¹H NMR (CDCl₃) δ 2.98, 3.62, 6.63, 7.62, 8.40.

Step 2. 6-Chloro-2-[[4-[5-(trifluoromethyl)pyridin-2-yl]-1-piperazinyl]methyl]imidazo[1,2-a]pyridine

10 A mixture of 1-(5-trifluoromethylpyridin-2-yl)piperazine (0.4803 g), 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.4177 g), triethylamine (0.231 g), and ethylene glycol (1 mL) is stirred at 80 °C for 70 min, after which additional 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (0.072 g) is added; thirty minutes later another portion (0.0517 g) is added. After stirring for a total of 2 h, 15 the mixture is cooled and partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated. Chromatography on silica gel using methanol/dichloromethane (4/96) and crystallization from ethyl ether/hexane gives 0.549 g of the title compound; mp 81-82 °C; MS m/z 395; IR (mineral oil) 1617, 1332, 1328, 1112, 1082 cm⁻¹. ¹H NMR (CDCl₃) δ 2.68, 3.69, 3.77, 6.62, 7.14, 7.52, 7.55, 7.61, 8.14, 8.38.

20 EXAMPLE 34 5-Chloro-2-[4-[(6-methylimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile. Refer to Chart E.

Following the general procedure of Example 9, Step 2, and making non-critical variations, 2-(chloromethyl)-6-methylimidazo[1,2-a]pyridine (Example 9, 25 Step 1; 0.2792 g) and 5-chloro-2-(piperazin-1-yl)benzonitrile (Example 32, Step 1; 0.4029 g) give 0.176 g of the title compound after chromatography and crystallization from ethyl ether/dichloromethane; mp 135-136 °C; MS m/z 365, 367; IR (mineral oil) 1486, 803, 1341, 825, 1333 cm⁻¹; ¹H NMR (CDCl₃) δ 2.31, 2.78, 3.25, 3.77, 6.92, 7.00, 7.39-7.50, 7.86.

30 EXAMPLE 35 6-Chloro-2-[[4-(5-chloropyridin-2-yl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine. Refer to Chart E.

Step 1. 1-(5-Chloropyridin-2-yl)piperazine. Refer to Chart C.

Following the general procedure of Example 33, Step 1, and making non-critical variations, 2,5-dichloropyridine (Aldrich; 5.10 g), piperazine (14.8 g), water 35 (50 mL), and N,N-dimethylacetamide (2 mL) give 3.42 g of 1-(5-chloropyridin-2-yl)piperazine; mp 92-107 °C; IR 1480, 1244, 1390, 1589, 815 cm⁻¹; ¹H NMR (CDCl₃)

WO 96/25414

PCT/US96/01114

δ 2.98, 3.47, 6.58, 7.42, 8.11.

Step 2. 6-Chloro-2-[[4-(5-chloropyridin-2-yl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine

Following the general procedure of Example 33, Step 2, and making non-critical variations, 1-(5-chloropyridin-2-yl)piperazine (0.424 g), 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.517 g), triethylamine (0.282 g), and ethylene glycol (2 mL) give, after crystallization from dichloromethane/ethyl ether, 0.621 g of the title compound; mp 137-138 °C; MS m/z 361, 363; IR 1593, 1480, 1245, 1324, 801, 1304 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.67, 3.55, 3.75, 6.57, 7.13, 7.41, 7.52, 7.53, 8.10, 8.14.

EXAMPLE 36 6-Chloro-2-[[4-(3-methoxyphenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine. Refer to Chart E.

Following the general procedure of Example 11 and making noncritical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.409 g), 1-(3-methoxyphenyl)piperazine dihydrochloride (Aldrich; 0.450 g), triethylamine (Aldrich; 0.686 g), and ethylene glycol (2 mL) give 0.440 g of the title compound after chromatography (silica gel, methanol/dichloromethane, 4/96) and crystallization from dichloromethane/ethyl ether/hexane; mp 132-133.5 °C; MS m/z 356; IR (mineral oil) 805, 2817, 1198, 1171, 1580, 1502 cm^{-1} . ^1H NMR (CDCl_3) δ 2.74, 3.24, 3.78, 6.41, 6.46, 6.55, 7.11-7.19, 7.52, 7.56, 8.14.

EXAMPLE 37 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl]methyl]-6-ethoxyimidazo[1,2-a]pyridine. Refer to Chart E.

Step 1. 2-(Chloromethyl)-6-ethoxyimidazo[1,2-a]pyridine. Refer to Chart A.

A mixture of 2-amino-5-ethoxypyridine (1.53 g; prepared by the method of Lombardino, *J. Med. Chem.* 1981, 24, 39-42), 1,3-dichloroacetone (Aldrich; 1.115 g), and dimethoxyethane (7 mL) is stirred overnight at room temperature. The mixture is concentrated under reduced pressure and ethanol (22.5 mL) is added. After the mixture is stirred for 30 min at 80 °C, it is cooled and then concentrated under reduced pressure. The residue is partitioned between dichloromethane and saturated aq. sodium bicarbonate. The combined organic layers are dried with MgSO_4 and concentrated under reduced pressure. The residue is chromatographed on silica gel using methanol/dichloromethane (4/96) and crystallized from ether/dichloromethane/hexane to give 0.94 g of 2-(chloromethyl)-6-ethoxyimidazo[1,2-a]pyridine in three crops; mp 95-96 °C; MS m/z 210, 212; IR (mineral oil) 1192, 1263, 810, 1537, 1511 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.45, 3.97, 4.75, 6.98, 7.46, 7.55, 7.58.

Step 2. 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl]methyl]-6-ethoxyimidazo[1,2-

WO 96/25414

PCT/US96/01114

a]pyridine

A mixture of 2-(chloromethyl)-6-ethoxyimidazo[1,2-*a*]pyridine (0.204 g), 1-(2,4-dichlorophenyl)piperazine (Example 31, Step 1; 0.2283 g), triethylamine (Aldrich; 0.15 mL), and THF (1.3 mL) is stirred at 75 °C until the reaction is judged complete
5 by thin layer chromatography. The cooled mixture is concentrated under reduced pressure and partitioned between dichloromethane and saturated aq. sodium bicarbonate. The combined organic layers are dried with MgSO₄ and concentrated under reduced pressure. The residue is chromatographed on silica gel using methanol/dichloromethane (2/98) and crystallized from ethyl acetate/ether to give
10 0.0936 g of the title compound; mp 171-172 °C; MS *m/z* 404, 406; IR (mineral oil) 1478, 1189, 797, 1508, 1273 cm⁻¹; ¹H NMR (CDCl₃) δ 1.45, 2.77, 3.08, 3.77, 3.98, 6.94, 7.17, 7.34, 7.45, 7.47, 7.60.

EXAMPLE 38 4-[4-[(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)methyl]-1-piperazinyl]-3-fluorobenzonitrile. Refer to Chart E.

15 Step 1. 3-Fluoro-4-(piperazin-1-yl)benzonitrile. Refer to Chart C.

A mixture of 3,4-difluorobenzonitrile (Aldrich; 4.076 g), piperazine (Aldrich; 12.554 g), and N,N-dimethylacetamide (20 mL) is stirred for 1.3 h at 120 °C. The mixture is then concentrated under reduced pressure to remove some of the N,N-dimethylacetamide and then partitioned between dichloromethane and saturated aq.
20 sodium bicarbonate. The combined organic layers are dried with MgSO₄ and concentrated under reduced pressure. The residue is crystallized from dichloromethane/ethyl acetate/methanol to give 1.99 g of material in two crops. The combined solids are then chromatographed on silica gel using methanol/dichloromethane (8/92) and the appropriate fractions combined and
25 concentrated. The residue is slurried in ethyl acetate, followed by the addition of methanol/dichloromethane and warming. The mixture is concentrated and the first solids to precipitate are removed by filtration. The filtrate is further concentrated to give 3.33 g of 3-fluoro-4-(piperazin-1-yl)benzonitrile; mp 85-85.5 °C ; IR (mineral oil) 1250, 897, 1613, 1505, 1515 cm⁻¹; ¹H NMR (CDCl₃) δ 1.90, 3.05, 3.18, 6.92, 7.26,
30 7.36.

Step 2. 4-[4-[(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)methyl]-1-piperazinyl]-3-fluorobenzonitrile

A mixture of 6-chloro-2-(chloromethyl)imidazo[1,2-*a*]pyridine (Example 4, step 1, 0.857 g), 3-fluoro-4-(piperazin-1-yl)benzonitrile (1.039 g), triethylamine (0.75 mL),
35 and THF (6 mL) is stirred for 3 h at 75-80 °C. The mixture is then concentrated under reduced pressure and the residue is partitioned between dichloromethane and

PCT/US96/01114

5 collected, washed with additional ethyl ether, and dried under reduced pressure to give 1.25 g of the title compound. A portion of this material is recrystallized from ethyl acetate; mp 132-133 °C ; IR (mineral oil) 1255, 1513, 1246, 801, 1504 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.74, 3.26, 3.77, 6.90, 7.13, 7.25, 7.34, 7.53, 8.13.

10 **EXAMPLE 39** 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl]methyl]-6-methoxyimidazo[1,2-a]pyridine. Refer to Chart E.

Step 1. **2-(Chloromethyl)-6-methoxyimidazo[1,2-a]pyridine.** Refer to Chart A.

15 mixture is concentrated under reduced pressure and ethanol (7.9 mL) is added. After the mixture has stirred for 30 min at 80 °C, it is cooled and concentrated under reduced pressure. The residue is partitioned between dichloromethane and saturated aq. sodium bicarbonate and the combined organic layers are dried with MgSO₄ and concentrated under reduced pressure. The residue is chromatographed
20 on silica gel using methanol/dichloromethane (4/96) to give 0.1392 g of 2-(chloromethyl)-6-methoxyimidazo[1,2-*a*]pyridine; ¹H NMR (CDCl₃) δ 3.82, 4.75, 6.99, 7.48, 7.56, 7.59.

Step 2. **2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl]methyl]-6-methoxy-**
imidazol[1,2-a]pyridine

25 A mixture of 2-(chloromethyl)-6-methoxyimidazo[1,2-*a*]pyridine (0.1392 g), 1-(2,4-dichlorophenyl)piperazine (Example 31, Step 1; 0.1662 g), triethylamine (Aldrich; 0.11 mL), and THF (2 mL) is stirred at 75 °C until the reaction is complete by thin layer chromatography. The cooled mixture is concentrated under reduced pressure and partitioned between dichloromethane and saturated aq. sodium bicarbonate. The combined organic layers are dried with MgSO₄ and concentrated under reduced pressure. The residue is chromatographed on silica gel using methanol/dichloromethane (4/96) and crystallized from ethyl acetate/ether to give 0.132 g of the title compound in two crops; mp 129.5-130.5 °C; MS *m/z* 390, 392; IR (mineral oil) 1479, 1166, 799, 1510, 1219 cm⁻¹; ¹H NMR (CDCl₃) δ 2.76, 3.08, 3.77, 3.81, 6.93, 6.97, 7.17, 7.34, 7.45, 7.49, 7.60.

EXAMPLE 40 2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-

WO 96/25414

PCT/US96/01114

4-fluorobenzonitrile. Refer to Chart E.

Step 1. 1-(2-Cyano-5-fluorophenyl)piperazine. Refer to Chart C.

A mixture of piperazine (Aldrich; 3.99 g), 2,4-difluorobenzonitrile, and N,N-dimethylacetamide (20 mL) is stirred for 1.5 h at 122 °C. After cooling, the mixture
5 is partitioned between dichloromethane and satd. aq. sodium bicarbonate. The organic layers are dried over magnesium sulfate and concentrated. The residue is chromatographed on silica gel and the appropriate fractions are combined and concentrated to give 1.44 g of 1-(2-cyano-5-fluorophenyl)piperazine; ¹H NMR (CDCl₃) δ 3.01, 3.30, 6.56, 6.63, 7.40.

10 Step 2. 2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-4-fluorobenzonitrile

Following the general procedure of Example 39, Step 2, and making non-critical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.298 g), 1-(2-cyano-5-fluorophenyl)piperazine (0.309 g), and THF (2 mL) are
15 converted to product, which is then chromatographed on silica gel using methanol/dichloromethane (2/98 to 4/96). Crystallization from dichloromethane/hexane, gives 0.348 g of material, which is recrystallized from ethyl acetate/dichloromethane to give 0.201 g of the title compound; mp 149-150 °C; MS *m/z* 369, 371; IR (mineral oil) 1625, 1260, 2221, 1514, 1332 cm⁻¹; ¹H NMR (CDCl₃) δ
20 2.69, 3.37, 3.76, 3.53, 6.61, 7.13, 7.39, 7.52, 7.53, 8.14.

EXAMPLE 41 6-Chloro-2-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]imidazo[1,2-a]pyridine. Refer to Chart E.

Following the general procedure of Example 39, Step 2, and making non-critical variations, 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step
25 1; 0.2982 g) and 1-[3-(trifluoromethyl)phenyl]piperazine (Aldrich; 0.34 mL) are converted to product, followed by chromatography on silica gel using methanol/dichloromethane (2/98). Crystallization from ethyl acetate and then from ethyl acetate/dichloromethane gives 0.053 g of the title compound; mp 145-145.5 °C; MS *m/z* 394; IR (mineral oil) 1117, 1163, 1451, 1073, 1339 cm⁻¹; ¹H NMR (CDCl₃) δ
30 2.75, 3.28, 3.78, 7.12, 7.34, 7.52, 7.54, 8.14.

EXAMPLE 42 1-[4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]phenyl]ethanone. Refer to Chart E.

Following the general procedure of Example 39, Step 2, 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.294 g), 4-
35 piperazinoacetophenone (Aldrich; 0.366 g), and THF (3 mL) are converted to product, which is chromatographed on silica gel using methanol/dichloromethane (2/98),

PCT/US96/01114

5 **EXAMPLE 43** 6-Chloro-2-[(4-phenyl-1-piperidinyl)methyl]imidazo[1,2-
a]pyridine. Refer to Chart E.

15 **EXAMPLE 44** 6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]-imidazo[1,2-a]pyridine-3-methanol. Refer to Chart G.

EXAMPLE 45 6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]-3-
30 [(phenylmethoxy)methyl]imidazo[1,2-a]pyridine
monomethanesulfonate. Refer to Chart G.

-45-

WO 96/25414

PCT/US96/01114

bicarbonate/brine. The organic layers are filtered through sodium sulfate and concentrated, and the residue is chromatographed on silica gel using methanol/dichloromethane (2/98) to give 0.061 g of 6-chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]-3-[(phenylmethoxy)methyl]imidazo[1,2-a]pyridine. The methanesulfonic acid salt is prepared by dissolving the product in dichloromethane and adding methanesulfonic acid (1 equivalent) and concentrating the mixture under reduced pressure. Crystallization from ethyl acetate/hexane affords 0.050 g of the title compound; mp 159-160.5 °C; MS m/z 514, 516; IR (mineral oil) 806, 1170, 1042, 1188, 1480 cm⁻¹. ¹H NMR (CDCl₃) δ 2.68, 3.02, 3.75, 4.57, 4.91, 6.92, 7.17, 7.36, 7.53, 8.14.

EXAMPLE 46 6-Bromo-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]-imidazo[1,2-a]pyridine. Refer to Chart E.

A mixture of 6-bromo-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 15, Step 1; 0.582 g), 1-(2,4-dichlorophenyl)piperazine (Example 31, Step 1; 0.548 g), triethylamine (Aldrich; 0.288 g), and THF (5 mL) is stirred at 80°C for 6 h, at which time it is cooled and then partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated. Chromatography of the residue on silica gel using methanol/dichloromethane (2/98) and crystallization gives 0.710 g of the title compound; mp 137-138 °C; MS m/z 438, 440; IR (mineral oil) 1479, 1341, 1058, 2810, 803 cm⁻¹. ¹H NMR (CDCl₃) δ 2.78, 3.09, 3.80, 6.96, 7.16-7.23, 7.35, 7.48, 7.55, 8.24.

EXAMPLE 47 6-Chloro-2-[[4-(3-chloro-4-methoxyphenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine. Refer to Chart E.

Step 1. 1-(3-Chloro-4-methoxyphenyl)piperazine. Refer to Chart B.

A mixture of 3-chloro-4-anisidine (Aldrich; 0.633 g), bis(2-chloroethyl)amine hydrochloride (Aldrich; 0.860 g), potassium carbonate (1.11 g), and N,N-dimethylacetamide (6 mL) is stirred at 100 °C for 17.5 h, at which time the mixture is cooled and partitioned between dichloromethane and water/sodium bicarbonate. The organic layers are dried over sodium sulfate, concentrated, and the residue is chromatographed on silica gel using methanol/dichloromethane (8/92) to give 0.297 g of 1-(3-chloro-4-methoxyphenyl)piperazine. ¹H NMR (CDCl₃) δ 3.05, 3.86, 6.80, 6.87, 6.99.

Step 2. 6-Chloro-2-[[4-(3-chloro-4-methoxyphenyl)-1-piperazinyl]methyl]-imidazo[1,2-a]pyridine

A mixture of 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.290 g), 1-(3-chloro-4-methoxyphenyl)piperazine (0.271 g), triethylamine

WO 96/25414

PCT/US96/01114

(Aldrich; 0.159 g), and ethylene glycol (2 mL) is stirred at 80 °C for 40 min, at which time another 0.031 g of 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine is added; after another 45 min, an additional 0.025 g of 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine is added. When the mixture has stirred for a total of 2 h, it is cooled and
5 partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated. The residue is chromatographed on silica gel using methanol/dichloromethane (2/98) to give 0.29 g of the title compound after crystallization from ethyl acetate/hexane; mp 99-100.5 °C; MS m/z 390, 392; IR (mineral oil) 1510, 1501, 795, 1072, 1321 cm⁻¹. ¹H NMR
10 (CDCl₃) δ 2.75, 3.14, 3.78, 3.84, 6.83, 6.97, 7.13, 7.52, 7.55, 8.14.

EXAMPLE 48 6-Chloro-2-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine. Refer to Chart E.

A mixture of 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.335 g), 1-(pyrimidin-2-yl)piperazine dihydrochloride (Aldrich; 0.395 g),
15 triethylamine (Aldrich; 0.522 g), THF (5 mL), and dichloromethane (5 mL) is heated at 80 °C for 45 min and then at 60 °C for 5 h, at which time DMF (1 mL) is added. After stirring for a total of 10.5 h, the mixture is allowed to cool and stir at room temperature for an additional 12 h. The solvents are then removed under reduced pressure and the residue is partitioned between dichloromethane and aq. sodium
20 bicarbonate. The organic layers are dried over sodium sulfate and concentrated. The residue is chromatographed on silica gel using methanol/dichloromethane (4/96) and the appropriate fractions are combined and concentrated to give 0.228 g of the title compound. Crystallization from methanol-dichloromethane-hexane gives 0.315 g of the title compound in two crops; mp 114-115 °C; MS m/z 328, 330; IR (mineral
25 oil) 1481, 1357, 1584, 1439, 1253, 1548 cm⁻¹. ¹H NMR (CDCl₃) δ 2.64, 3.76, 3.87, 6.48, 7.12, 7.52, 7.54, 8.14, 8.30.

EXAMPLE 49 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl]methyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine monomethanesulfonate. Refer to Chart E.

30 Step 1. 2-(Chloromethyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine

A mixture of 2-amino-5-trifluoromethylpyridine (Fluorochem; 3.19 g), 1,3-dichloroacetone (Aldrich; 3.00 g), and dimethoxyethane (Aldrich; 15 mL) is stirred at room temperature for 4 days. The resulting solid is collected and washed with several milliliters of dimethoxyethane. The solid is then taken up in ethanol (30
35 mL) and the mixture is heated at 80 °C for 2.5 h, at which time diisopropylethylamine (Aldrich; 3.5 mL) is added. After stirring with heating an

WO 96/25414

PCT/US96/01114

additional 3.5 h. the mixture is cooled and the solvent is removed under reduced pressure. The residue is partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are filtered through sodium sulfate and concentrated; the residue is chromatographed on silica gel using
5 methanol/dichloromethane (1/99) to give 3.33 g of 2-(chloromethyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine. ^1H NMR (CDCl_3) δ 4.78, 7.36, 7.69, 7.73, 8.48.

Step 2. 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl]methyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine monomethanesulfonate

10 A mixture of 2-(chloromethyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine (0.452 g), 1-(2,4-dichlorophenyl)piperazine (Example 31, Step 1; 0.468 g), diisopropylethylamine (Aldrich; 0.299 g), and THF (4 mL) is stirred at reflux for 21 h. After cooling, the mixture is partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate, concentrated.
15 and the residue chromatographed on silica gel using methanol/dichloromethane (2.5/97.5) to give 0.64 g of 2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine. The methanesulfonate salt is prepared by dissolving 2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine in ethyl acetate/hexane and adding
20 methanesulfonic acid (0.143 g) dissolved in methanol. The mixture is concentrated under reduced pressure and the residue is crystallized from ethyl acetate to give 0.691 g of the title compound; mp 161-162 °C; MS m/z 428; IR (mineral oil) 1162, 1225, 1033, 1130, 1142, 1337 cm^{-1} . ^1H NMR (CDCl_3) δ 2.78, 3.09, 3.83, 6.96, 7.18, 7.31, 7.35, 7.66, 7.68, 8.47.

25 EXAMPLE 50 2-[[4-(4-Chlorophenyl)-1-piperazinyl]methyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine. Refer to Chart E.

Following the same general procedure as for Example 49, Step 2, and making non-critical variations, 2-(chloromethyl)-6-trifluoromethylimidazo[1,2-a]pyridine (Example 49, Step 1; 0.435 g), 1-(4-chlorophenyl)piperazine dihydrochloride (Aldrich;
30 0.550 g), diisopropylethylamine (Aldrich; 0.815 g), and THF (6 mL) give 0.30 g of 2-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine after crystallization from ethyl acetate/hexane; mp 128-135 °C; MS m/z 394; IR (mineral oil) 1331, 1141, 1127, 1055, 1500, 830 cm^{-1} . ^1H NMR (CDCl_3) δ 2.74, 3.20, 3.80, 6.83, 7.19, 7.31, 7.66, 7.68, 8.47.

35 EXAMPLE 51 2-[[4-(4-Chlorophenyl)-1-piperazinyl]methyl]-6-phenylimidazo[1,2-a]pyridine. Refer to Chart H.

WO 96/25414

PCT/US96/01114

A mixture of 6-bromo-2-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine (Example 23; 0.091 g), tetrakis(triphenylphosphine)palladium (0) (Aldrich; 0.0078 g), and dimethoxyethane (2 mL) is stirred at room temperature for 10 min, at which time phenylboric acid (Aldrich; 0.0306 g) is added, followed by sodium bicarbonate (0.0565 g) in water (1 mL). The mixture is stirred at reflux for 3 h and then allowed to cool. Dimethoxyethane is removed under reduced pressure and the residue is partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated. The residue is chromatographed on silica gel using acetone/dichloromethane/methanol (50/200/1) to give 0.027 g of the title compound. MS m/z 402; ^1H NMR (CDCl_3) δ 2.76, 3.21, 3.80, 6.84, 7.19, 7.37-7.58, 7.61, 7.64, 8.26.

EXAMPLE 52 4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-3-fluorobenzamide. Refer to Chart F.

A mixture of 4-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-3-fluorobenzonitrile (Example 38; 0.298 g), pulverized NaOH (0.159 g), tert-butanol (3 mL), and 5 drops of 30% hydrogen peroxide in water is heated at 90 °C for 5.5 h. The mixture is then concentrated under reduced pressure and the resulting solids are slurried in water, collected by filtration, and washed and dried under reduced pressure. The solids are then crystallized from dichloromethane/methanol to give 0.180 g of material, which is chromatographed on silica gel using methanol/dichloromethane (4/96). After combining and concentrating the appropriate fractions, the residue is crystallized from ethyl acetate/dichloromethane/methanol to give 0.084 g of the title compound; mp 253-255 °C; MS m/z 387, 389; IR (mineral oil) 1435, 1620, 1678, 1225, 1505 cm^{-1} ; ^1H NMR ($\text{CDCl}_3 + \text{CD}_3\text{OD}$) δ 2.77, 3.38, 3.80, 6.94, 7.19, 7.53, 7.62, 8.23.

EXAMPLE 53 (RS)-4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-3-methylpiperazin-1-yl]benzamide. Refer to Chart E.

Step 1. (RS)-4-(3-Methylpiperazin-1-yl)benzamide. Refer to Chart C.

A mixture of 4-fluorobenzamide (Aldrich; 2.432 g), (RS)-2-methylpiperazine (Aldrich; 4.247 g), and water (9 mL) is heated at 100 °C for 7 days. The mixture is then cooled to 41 °C and water is added. The solid is collected, washed with water and toluene and dried under reduced pressure to give 3.37 g of (RS)-4-(3-methylpiperazin-1-yl)benzamide; ^1H NMR (CDCl_3 , CD_3OD) δ 1.17, 2.48, 2.82, 2.94-3.15, 3.04, 3.68, 6.89, 7.73.

Step 2. (RS)-4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-3-methylpiperazin-1-yl]benzamide

WO 96/25414

PCT/US96/01114

Following the general procedure of Example 39. Step 2. and making non-critical variations. 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4. Step 1; 0.201 g) and (RS)-4-(2-methylpiperazine)benzamide (0.253 g) are converted to crude product, which is chromatographed on silica gel using methanol/dichloromethane (4/96 to 8/92), followed by crystallization from ethyl acetate/dichloromethane/methanol, to give 0.1454 g of material. Re-chromatography on silica gel using methanol/dichloromethane/ NH_4OH (4/96/0.5) and trituration of the material from the product fractions with ethyl ether gives the title compound; mp 202-204 °C; MS m/z 383, 385; IR (mineral oil) 1609, 1393, 1251, 1681, 1423 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.20, 2.51, 2.86, 3.66, 3.96, 6.90, 7.03, 7.24, 7.55, 7.70, 7.72, 7.85, 8.79.

EXAMPLE 54 2-[[4-(4-Chlorophenyl)-1-piperazinyl]methyl]-8-methylimidazo[1,2-a]pyridine. Refer to Chart E.

Step 1. 2-(Chloromethyl)-8-methylimidazo[1,2-a]pyridine

A mixture of 2-amino-3-picoline (Aldrich; 13.23 g), 1,3-dichloroacetone (Aldrich; 18.92 g), and dimethoxyethane (131 mL) is stirred at room temperature for 2 days. The mixture is then concentrated under reduced pressure and ethanol (100 mL) is added. The mixture is heated at 80 °C for 2.3 h. After cooling, the mixture is concentrated under reduced pressure and the residue is partitioned between saturated aq. sodium bicarbonate and dichloromethane. The combined organic layers are dried with MgSO_4 and concentrated under reduced pressure. The residue is chromatographed on silica gel first using methanol/dichloromethane (4/96) and a second time using methanol/dichloromethane (2/98). The appropriate fractions are combined and concentrated, and the residue is crystallized from ethyl acetate/dichloromethane/ether to give a first crop of 5.854 g and a second crop of 1.079 g of 2-(chloromethyl)-8-methylimidazo[1,2-a]pyridine; MS m/z 180, 182; IR (mineral oil) 752, 709, 1259, 773, 1493 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.61, 4.80, 6.70, 6.97, 7.62, 7.95.

Step 2. 2-[[4-(4-Chlorophenyl)-1-piperazinyl]methyl]-8-methylimidazo[1,2-a]pyridine

A mixture of 2-(chloromethyl)-8-methylimidazo[1,2-a]pyridine (0.297 g), 1-(4-chlorophenyl)piperazine dihydrochloride (Aldrich; 0.534 g), triethylamine (0.8 mL), THF (6 mL), and DMF (2 mL) is heated at 75 °C for 4 hours. Diisopropylethylamine (0.3 mL) is added and the mixture is stirred another hour, at which time the mixture is concentrated under reduced pressure and the residue is partitioned between saturated aq. sodium bicarbonate and dichloromethane. The organic layers are dried with MgSO_4 and concentrated under reduced pressure. The residue is

WO 96/25414

PCT/US96/01114

chromatographed on silica gel using methanol/dichloromethane (4/96). The appropriate fractions are combined and concentrated and the residue is crystallized from ethyl acetate/hexane to give 0.231 g of the title compound; mp 102-104 °C; MS m/z 340; IR (mineral oil) 1495, 1338, 2819, 1227, 743 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.61, 2.78, 3.22, 3.85, 6.68, 6.82, 6.94, 7.18, 7.58, 7.95.

EXAMPLE 55 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl]methyl]-8-methylimidazo[1,2-a]pyridine monomaleic acid salt. Refer to Chart E.

A mixture of 2-(chloromethyl)-8-methylimidazo[1,2-a]pyridine (Example 54, Step 1; 0.294 g), 1-(2,4-dichlorophenyl)piperazine (Example 31, Step 1; 0.396 g) diisopropylethylamine (0.35 mL), and THF (2 mL) is heated at 75 °C for 5 hours. The mixture is then concentrated under reduced pressure, partitioned between saturated aq. sodium bicarbonate and dichloromethane, and the combined organic layers are dried with MgSO_4 and concentrated under reduced pressure. The residue is chromatographed on silica gel using methanol/dichloromethane (4/96) and the appropriate fractions are combined and concentrated to give 2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]-8-methylimidazo[1,2-a]pyridine. The maleic acid salt is formed by adding maleic acid (0.101 g) to the product dissolved in dichloromethane/methanol. Crystallization from dichloromethane/ether gives 0.2192 g of the title compound; mp 151-152 °C; MS m/z 374, 376; IR (mineral oil) 1482, 1345, 1570, 1357, 867 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.61, 2.80, 3.09, 3.85, 6.67, 6.95, 7.18, 7.35, 7.56, 7.95.

EXAMPLE 56 2-[[4-(4-Chlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine.

Following the general procedure of Example 38, Step 2, and making non-critical variations, 2-(chloromethyl)imidazo[1,2-a]pyridine (Example 2, Step 1; 0.25 g) and 1-(4-chlorophenyl)piperazine dihydrochloride (Aldrich; 0.45 g) give 0.25 g of the title compound after chromatography on silica gel using methanol/dichloromethane (4/96), pooling of the appropriate fractions, and crystallization from dichloromethane/ethyl ether; mp 138-139 °C; IR (mineral oil) 1339, 1498, 765, 814, 1223 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.75, 3.20, 3.79, 6.79, 7.17, 7.56, 7.57, 8.08.

EXAMPLE 57 2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-5-fluorobenazmide.

Following the general procedure of Example 52 and making non-critical variations, 2-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-5-fluorobenzonitrile (Example 21; 0.061 g) is converted to 0.021 g of the title compound after chromatography on silica gel using methanol/dichloromethane (4/96) and

WO 96/25414**PCT/US96/01114**


crystallization from dichloromethane/hexane; mp 197-198 °C; ms m/z at 387, 389; IR (mineral oil) 1669, 1328, 1501, 1428, 825 cm⁻¹.

WO 96/25414

PCT/US96/01114


FORMULA CHART

5




I

10




II

15




III

20




IIIA

25



IV

30





V

WO 96/25414

PCT/US96/01114


CHART A



WO 96/25414

PCT/US96/01114


CHART B



WO 96/25414


PCT/US96/01114

CHART C




C-1

+



C-2




C-3

WO 96/25414

PCT/US96/01114


CHART D



WO 96/25414


PCT/US96/01114

CHART E




E-1 (D-1)


+




E-2



E-3



E-4





E-5 (D-6)

WO 96/25414

PCT/US96/01114


CHART F




WO 96/25414

PCT/US96/01114


CHART G



G-1 (D-6) (E-5)



G-2





G-3

WO 96/25414

PCT/US96/01114


CHART H






WO 96/25414

PCT/US96/01114

CHART I




+




WO 96/25414

PCT/US96/01114


CHART J




J-1




J-2



J-3



J-4




J-5


WO 96/25414

PCT/US96/01114

CHART K



K-1




K-2


WO 96/25414

PCT/US96/01114


CHART L




E-1




E-6




E-2




E-7




E-3




E-8




E-4



E-9



E-5




E-10


WO 96/25414

PCT/US96/01114


CHART L (Continued)




E-11




E-16




E-12




E-17




E-13




E-18




E-14



E-19



E-15




E-20


WO 96/25414

PCT/US96/01114


CHART L (Continued)




E-21




E-26




E-22




E-27




E-23




E-28




E-24



E-29



E-25













E-30

WO 96/25414

PCT/US96/01114











CHART L (Continued)



WO 96/25414

PCT/US96/01114





CHART L (Continued)



WO 96/25414

PCT/US96/01114



CHART L (Continued)




WO 96/25414

PCT/US96/01114

CHART L (Continued)



E-56



E-57


WO 96/25414

PCT/US96/01114

CLAIMS

1. A compound of the formula I

5



I

wherein R_1 and R_2 are the same or different and are

- 10 a) H,
 b) fluoro,
 c) chloro,
 d) bromo,
 e) iodo.
 15 f) C_1 - C_4 alkyl,
 g) C_3 - C_7 cycloalkyl,
 h) CN,
 i) $CONR_{11}R_{12}$,
 j) $SO_2NR_{11}R_{12}$,
 20 k) $NR_{11}R_{12}$,
 l) $N(R_{11})SO_2R_{12}$,
 m) $N(R_{11})CO(R_{12})$,
 n) NO_2 ,
 o) OH,
 25 p) $O(C_1$ - C_3 alkyl),
 q) O-phenyl,
 r) O- CF_3 ,
 s) O- SO_2CF_3 ,
 t) SH,
 30 u) $S(C_1$ - C_3 alkyl),
 v) thiazolyl,
 w) imidazolyl,
 x) oxadiazolyl,
 y) aryl optionally substituted with R_{13} , or
 35 z) CF_3 ;

wherein R_3 is

WO 96/25414

PCT/US96/01114

- a) H,
 b) halo.
 c) CN,
 d) OH,
 5 e) OR_4 ,
 f) $(\text{CH}_2)_n\text{OH}$.
 g) $(\text{CH}_2)_n\text{OR}_4$.
 h) $(\text{CH}_2)_n\text{OCOR}_4$.
 i) $(\text{CH}_2)_n\text{OCOOR}_4$.
 10 j) $(\text{CH}_2)_n\text{OCONR}_{11}\text{R}_{12}$.
 k) $(\text{CH}_2)_n\text{N}(\text{R}_{11})\text{CONR}_{11}\text{R}_{12}$.
 l) $\text{C}_1\text{-C}_4$ alkyl,
 m) $(\text{CH}_2)_p\text{COOR}_4$.
 n) $(\text{CH}_2)_n\text{CONR}_{11}\text{R}_{12}$.
 15 o) CHO, or
 p) $(\text{CH}_2)_n\text{-A-(CH}_2)_m\text{-Ar(R}_8\text{)(R}_9\text{)(R}_{10}\text{)}$;

wherein A is

- a) CH_2 ,
 b) O,
 20 c) S, or
 d) $\text{N(R}_{11}\text{)}$;

wherein R_4 , R_5 , R_6 and R_7 are the same or different and are

- a) H,
 b) $\text{C}_1\text{-C}_4$ alkyl,
 25 c) $\text{C}_3\text{-C}_7$ cycloalkyl,
 d) $\text{C}_1\text{-C}_3\text{-alkyl-C}_3\text{-C}_7$ cycloalkyl, or
 e) aryl optionally substituted with R_{13} ;

wherein W is

- a) N, or
 30 b) CH;

wherein X is

- a) absent, or
 b) $\text{N(R}_4\text{)}$;

wherein Y is

- 35 a) phenyl,
 b) 2-, 3- or 4-pyridinyl.

WO 96/25414

PCT/US96/01114

- c) 2-, 4- or 5-pyrimidinyl,
 d) 3- or 4-pyridazinyl,
 e) 2-pyrazinyl.
 f) 2-, 3-, 6- or 7-imidazo[1,2-a]pyridinyl,
 5 g) 2-benzoxazolyl,
 h) 2-thiobenzoxazolyl,
 i) 2-thiazolyl,
 j) 1,3-dihydro-2H-benzimidazol-2-one, or
 k) 1,3-dihydro-3-methyl-2H-benzimidazol-2-one;
- 10 wherein R_8 , R_9 and R_{10} are the same or different and are
 a) hydrogen,
 b) fluoro,
 c) chloro,
 d) bromo,
 15 e) iodo,
 f) C_1 - C_4 alkyl,
 g) C_3 - C_7 cycloalkyl,
 h) CN,
 i) $CONR_{11}R_{12}$
 20 j) $SO_2NR_{11}R_{12}$,
 k) $NR_{11}R_{12}$,
 l) $N(R_{11})SO_2R_{12}$,
 m) $N(R_{11})COR_{12}$,
 n) NO_2 ,
 25 o) OH,
 p) $O(C_1$ - C_3 alkyl),
 q) O-aryl optionally substituted with R_{13} ,
 r) $O-CF_3$,
 s) $O-SO_2CF_3$,
 30 t) SH,
 u) $S(C_1$ - C_3 alkyl),
 v) thiazolyl,
 w) imidazolyl,
 x) oxadiazolyl,
 35 y) phenyl, r
 z) 2-, 3- or 4-pyridinyl;

WO 96/25414

PCT/US96/01114

- a1) CF_3 ,
b1) $-\text{C}(\text{O})\text{C}_1\text{-C}_4\text{alkyl}$,
c1) $\text{C}(\text{O})\text{OR}_4$, or
d1) SO_2 -phenyl optionally substituted with R_{13} ;
- 5 wherein R_{11} and R_{12} are the same or different and are
a) H.
b) $\text{C}_1\text{-C}_4$ alkyl,
c) $\text{C}_3\text{-C}_7$ cycloalkyl,
d) $\text{C}_1\text{-C}_3$ alkyl- $\text{C}_3\text{-C}_7$ cycloalkyl, or
10 e) aryl optionally substituted with R_{13} ;
- when R_{11} and R_{12} occur in $\text{NR}_{11}\text{R}_{12}$, R_{11} and R_{12} may be taken together with a methylene group or a heteroatom to form a five- or six-membered ring, such as piperazine, morpholine, thiomorpholine, piperidine, or pyrrolidine;
wherein aryl is
- 15 a) phenyl,
b) naphthyl,
c) 2-, 3- or 4-pyridinyl, or
d) 2-, 4- or 5-pyrimidinyl;
- wherein R_{13} is
- 20 a) H,
b) fluoro,
c) chloro,
d) bromo.
e) iodo,
25 f) CH_3 ,
g) CF_3 ,
h) CN,
i) OH, or
j) OCH_3 ;
- 30 wherein n is one (1) to four (4) inclusive;
wherein m is zero (0) to four (4) inclusive;
wherein p is two (2) to four (4) inclusive;
and pharmaceutically acceptable salts and racemic mixtures thereof;
with the following provisos:
- 35 1) when R_1 or R_2 is $-\text{CONR}_{11}\text{R}_{12}$, then R_{11} and R_{12} are not both H: and
2) when R_8 , R_9 or R_{10} is $-\text{CONR}_{11}\text{R}_{12}$ wherein R_{11} and R_{12} are both H.


WO 96/25414

PCT/US96/01114

then X is absent.

2. The compound of claim 1 of the formula II

5



II

10 wherein R_1 and R_2 are the same or different and are

- a) H,
- b) chloro,
- c) bromo,
- d) CH_3
- 15 e) $\text{O}(\text{C}_1\text{-C}_2 \text{ alkyl})$,
- f) phenyl, or
- g) CF_3 ;

wherein R_3 is

- a) H,
- 20 b) $(\text{CH}_2)\text{OH}$, or
- c) $\text{CH}_2\text{-O-CH}_2\text{-phenyl}$;

wherein R_6 is

- a) H, or
- b) CH_3 ;

25 wherein W is

- a) N, or
- b) CH;

wherein Y is

- a) phenyl,
- 30 b) 2-pyridinyl,
- c) 2-pyrimidinyl,
- d) 1,3-dihydro-2H-benzimidazol-2-one, or
- e) 1,3-dihydro-3-methyl-2H-benzimidazol-2-one;

wherein R_8 and R_9 are the same or different and are

- 35 a) hydrogen.
- b) fluoro.


WO 96/25414

PCT/US96/01114

- 5 c) chloro.
d) CN,
e) CONH₂
f) OCH₃,
g) CF₃,
h) C(O)CH₃, or
i) SO₂NH₂;

and pharmaceutically acceptable salts and racemic mixtures thereof.

- 10 3. The compound of claim 2 of the formula III



III

15

wherein R₁ and R₂ are the same or different and are

- 20 a) H,
b) chloro,
c) bromo,
d) CH₃,
e) OCH₃,
f) OCH₂CH₃,
g) phenyl, or
h) CF₃;

25 wherein R₃ is

- a) H,
b) CH₂OH.
c) CH₂-O-CH₂-phenyl;

wherein R₆ is

- 30 a) H, or
b) CH₃;

wherein R₈ and R₉ are the same or different and are:

- 35 a) hydrogen,
b) fluoro,
c) chloro,
d) CN,


WO 96/25414

PCT/US96/01114

- e) CONH_2 ,
 f) OCH_3 ,
 g) CF_3 ,
 h) C(O)CH_3 , or
 5 i) SO_2NH_2 ;

and pharmaceutically acceptable salts and racemic mixtures thereof.

4. The compound of claim 3 of the formula IIIA



wherein R_1 is


- 15 a) H,
 b) bromo,
 c) chloro, or
 d) CH_3 ;

wherein R_8 and R_9 are the same or different and are

- 20 a) H or
 b) chloro;

and pharmaceutically acceptable salts and racemic mixtures thereof.

5. The compound of claim 2 of the formula IV



30 wherein R_2 is chloro;

wherein Y is


- a) phenyl,
 b) 1,3-dihydro-2H-benzimidazol-2-one, or
 c) 1,3-dihydro-3-methyl-2H-benzimidazol-2-one;

35 and pharmaceutically acceptable salts and racemic mixtures thereof.

WO 96/25414

PCT/US96/01114

6. The compound of claim 2 of the formula V



wherein R_2 is chloro;

wherein Y is

- 10 a) 2-pyridinyl, or
 b) 2-pyrimidinyl;

wherein R_8 and R_9 are the same or different and are

- a) H,
 b) Cl, or
 c) CF_3 ;

15 and pharmaceutically acceptable salts and racemic mixtures thereof.

7. The compound of claim 2 selected from the group consisting of:

- 6-Chloro-2-[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
 4-[4-[(Imidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzenesulfonamide;
 20 4-[4-[(Imidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
 4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
 4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzene-
 sulfonamide;
 2-[[4-(4-Fluorophenyl)-1-piperazinyl]methyl]-7-methylimidazo[1,2-a]pyridine;
 25 4-[4-[(7-Methylimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
 1-[1-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-4-piperidinyl]-1,3-dihydro-
 2H-benzimidazol-2-one;
 2-[[4-(4-Fluorophenyl)-1-piperazinyl]methyl]-6-methylimidazo[1,2-a]pyridine;
 4-[4-[(6-Methylimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
 30 6-Chloro-2-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
 6-Chloro-2-[[4-(2-chlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
 2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile;
 1-[1-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-4-piperidinyl]-1,3-dihydro-3-
 methyl-2H-benzimidazol-2- ne;
 35 6-Bromo-2-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
 4-[4-[(6-Bromoimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;

WO 96/25414

PCT/US96/01114

- 6-Chloro-2-[[4-(4-chlorophenyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
 6-Chloro-2-[[4-(3-chlorophenyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
 6,8-Dichloro-2-[[4-(4-fluorophenyl)-1-piperazinyl)methyl]imidazo[1,2-
 a]pyridine;
- 5 2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
 2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-5-fluoro-
 benzonitrile;
 4-[4-[(6,8-Dichloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
 6-Bromo-2-[[4-(4-chlorophenyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
- 10 8-Chloro-2-[[4-(4-fluorophenyl)-1-piperazinyl)methyl]-6-
 trifluoromethylimidazo[1,2-a]pyridine;
 6-Chloro-2-[[4-(2-fluorophenyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
 6-Chloro-2-[(4-phenyl-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
 4-[4-[(8-Chloro-6-trifluoromethylimidazo[1,2-a]pyridin-2-yl)methyl]-1-
 15 piperazinyl]benzamide;
 6-Chloro-2-[[4-(3,4-dichlorophenyl)-1-piperazinyl)methyl]imidazo[1,2-
 a]pyridine;
 3-Chloro-4-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-
 piperazinyl]benzonitrile;
- 20 3-Chloro-4-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-
 piperazinyl]benzamide;
 6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl)methyl]imidazo[1,2-
 a]pyridine;
 5-Chloro-2-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-
 25 piperazinyl]benzonitrile;
 6-Chloro-2-[[4-[5-(trifluoromethyl)pyridin-2-yl]-1-
 piperazinyl)methyl]imidazo[1,2-a]pyridine;
 5-Chloro-2-[4-[(6-methylimidazo[1,2-a]pyridin-2-yl)methyl]-1-
 piperazinyl]benzonitrile;
- 30 6-Chloro-2-[[4-(5-chloropyridin-2-yl)-1-piperazinyl)methyl]imidazo[1,2-
 a]pyridine;
 6-Chloro-2-[[4-(3-methoxyphenyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl)methyl]-6-ethoxyimidazo[1,2-
 a]pyridine;
- 35 4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-3-
 fluorobenzonitrile;

WO 96/25414

PCT/US96/01114

- 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl)methyl]-6-methoxyimidazo[1,2-a]pyridine;
- 2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-4-fluorobenzonitrile;
- 5 6-Chloro-2-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
- 1-[4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]phenyl]ethanone;
- 6-Chloro-2-[(4-Phenyl-1-piperidinyl)methyl]imidazo[1,2-a]pyridine;
- 10 6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine-3-methanol;
- 6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl)methyl]-3-[(phenylmethoxy)methyl]imidazo[1,2-a]pyridine monomethanesulfonate;
- 6-Bromo-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl)methyl]imidazo[1,2-
- 15 a]pyridine;
- 6-Chloro-2-[[4-(3-chloro-4-methoxyphenyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
- 6-Chloro-2-[[4-(2-pyrimidinyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
- 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl)methyl]-6-(trifluoro-
- 20 methyl)imidazo[1,2-a]pyridine; monomethanesulfonate
- 2-[[4-(4-Chlorophenyl)-1-piperazinyl)methyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine;
- 2-[[4-(4-Chlorophenyl)-1-piperazinyl)methyl]-6-phenylimidazo[1,2-a]pyridine;
- 4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-3-
- 25 fluorobenzamide;
- (RS)-4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-3-methylpiperazin-1-yl]benzamide;
- 2-[[4-(4-Chlorophenyl)-1-piperazinyl)methyl]-8-methylimidazo[1,2-a]pyridine;
- 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl)methyl]-8-methylimidazo[1,2-
- 30 a]pyridine monomaleic acid salt;
- 2-[[4-(4-Chlorophenyl)-1-piperazinyl)methyl]imidazol[1,2-a]pyridine; and
- 2-[4-[(6-Chloroimidazol[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-5-fluorobenazmide.
- 35 8. The compound of claim 4 selected from the group consisting of:
6-Bromo-2-[[4-(4-chlorophenyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;

WO 96/25414

PCT/US96/01114

- 6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
 2-[[4-(4-Chlorophenyl)-1-piperazinyl]methyl]-8-methylimidazo[1,2-a]pyridine;
 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl]methyl]-8-methylimidazo[1,2-a]pyridine monomaleic acid salt; and
 2-[[4-(4-Chlorophenyl)-1-piperazinyl]methyl]imidazol[1,2-a]pyridine.
9. A compound of claim 1 when used to treat a patient having a disease associated with the dopaminergic system of the central nervous system or the heart.
10. The compound of claim 9 wherein the disease is selected from the group consisting of: schizophrenia, psychosis, depression, anxiety, drug addiction, and cardiac arrhythmias and fibrillation.
11. A compound of claim 10 wherein the compound is selected from the group consisting of:
- 6-Chloro-2-[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
 4-[4-[(Imidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzenesulfonamide;
 4-[4-[(Imidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
 4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
 4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzenesulfonamide;
 2-[[4-(4-Fluorophenyl)-1-piperazinyl]methyl]-7-methylimidazo[1,2-a]pyridine;
 4-[4-[(7-Methylimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
 1-[1-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one;
 2-[[4-(4-Fluorophenyl)-1-piperazinyl]methyl]-6-methylimidazo[1,2-a]pyridine;
 4-[4-[(6-Methylimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
 6-Chloro-2-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
 6-Chloro-2-[[4-(2-chlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
 2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile;
 1-[1-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-4-piperidinyl]-1,3-dihydro-3-methyl-2H-benzimidazol-2-one;
 6-Bromo-2-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
 4-[4-[(6-Bromoimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
 6-Chloro-2-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;

WO 96/25414

PCT/US96/01114

- 6-Chloro-2-[[4-(3-chlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
6,8-Dichloro-2-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
- 5 2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-5-fluorobenzonitrile;
- 4-[4-[(6,8-Dichloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
6-Bromo-2-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
8-Chloro-2-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-6-trifluoromethyl-
- 10 imidazo[1,2-a]pyridine;
6-Chloro-2-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
6-Chloro-2-[(4-phenyl-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
4-[4-[(8-Chloro-6-trifluoromethylimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzamide;
- 15 6-Chloro-2-[[4-(3,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
3-Chloro-4-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile;
- 3-Chloro-4-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-
- 20 piperazinyl]benzamide;
6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
- 5-Chloro-2-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile;
- 25 6-Chloro-2-[[4-[5-(trifluoromethyl)pyridin-2-yl]-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
5-Chloro-2-[4-[(6-methylimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile;
- 6-Chloro-2-[[4-(5-chloropyridin-2-yl)-1-piperazinyl]methyl]imidazo[1,2-
- 30 a]pyridine;
6-Chloro-2-[[4-(3-methoxyphenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;
2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl]methyl]-6-ethoxyimidazo[1,2-a]pyridine;
- 4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-3-
- 35 fluorobenzonitrile;
2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl]methyl]-6-methoxyimidazo[1,2-

WO 96/25414

PCT/US96/01114

- a]pyridine;
 2-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-4-fluorobenzonitrile;
 6-Chloro-2-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl)methyl]imidazo[1,2-
 5 a]pyridine;
 1-[4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]phenyl]ethanone;
 6-Chloro-2-[(4-Phenyl-1-piperidinyl)methyl]imidazo[1,2-a]pyridine;
 6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl)methyl]imidazo[1,2-
 10 a]pyridine-3-methanol;
 6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl)methyl]-3-[(phenylmethoxy)methyl]imidazo[1,2-a]pyridine monomethanesulfonate;
 6-Bromo-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
 15 6-Chloro-2-[[4-(3-chloro-4-methoxyphenyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
 6-Chloro-2-[[4-(2-pyrimidinyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;
 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl)methyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine; monomethanesulfonate
 20 2-[[4-(4-Chlorophenyl)-1-piperazinyl)methyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine;
 2-[[4-(4-Chlorophenyl)-1-piperazinyl)methyl]-6-phenylimidazo[1,2-a]pyridine;
 4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-3-fluorobenzamide;
 25 (RS)-4-[4-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-3-methylpiperazin-1-yl]benzamide;
 2-[[4-(4-Chlorophenyl)-1-piperazinyl)methyl]-8-methylimidazo[1,2-a]pyridine;
 2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl)methyl]-8-methylimidazo[1,2-a]pyridine monomaleic acid salt;
 30 2-[[4-(4-Chlorophenyl)-1-piperazinyl)methyl]imidazol[1,2-a]pyridine; and
 2-[4-[(6-Chloroimidazol[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]-5-fluorobenazmide.

12. A compound of claim 11 wherein the compound is selected from the group
 35 consisting of:

6-Bromo-2-[[4-(4-chlorophenyl)-1-piperazinyl)methyl]imidazo[1,2-a]pyridine;

WO 96/25414

PCT/US96/01114

6-Chloro-2-[[4-(2,4-dichlorophenyl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine;

2-[[4-(4-Chlorophenyl)-1-piperazinyl]methyl]-8-methylimidazo[1,2-a]pyridine;

2-[[4-(2,4-Dichlorophenyl)-1-piperazinyl]methyl]-8-methylimidazo[1,2-

5 a]pyridine monomaleic acid salt; and

2-[[4-(4-Chlorophenyl)-1-piperazinyl]methyl]imidazol[1,2-a]pyridine.

13. A compound of claim 1 when used to lessen the extrapyramidal motor side effects in a patient, who is being treated with an anti-psychotic drug.

10

14. A compound of claim 13 wherein the anti-psychotic drug is selected from the group consisting of chlorpromazine, thioridazine, haloperidol, and risperidone.

15. A compound of claim 13 wherein the dose of the anti-psychotic drug is administered at a higher dose than when the drug is administered alone.

15

INTERNATIONAL SEARCH REPORT

International Application No

PC1/US 96/01114

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D471/04 A61K31/435 //(C07D471/04,235:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,94 24105 (MERCK SHARP & DOHME) 27 October 1994 see page 2, line 16 - line 25; claim 1 ---	1,9
A	EP,A,0 050 563 (SYNTHELABO) 28 April 1982 see page 6 and page 13, line 29 - page 14, line 4 -----	1,9

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

28 May 1996

Date of mailing of the international search report

06. 06. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/01114

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9424105	27-10-94	AU-B- 6435594	08-11-94
EP-A-50563	28-04-82	FR-A- 2492382	23-04-82
		AT-T- 7393	15-05-84
		AU-B- 544345	23-05-85
		AU-B- 7668781	28-04-83
		CA-A- 1157470	22-11-83
		JP-C- 1465107	10-11-88
		JP-A- 57098283	18-06-82
		JP-B- 63007545	17-02-88
		LU-A- 88228	03-02-94
		OA-A- 7076	31-01-84
		US-A- 4382938	10-05-83
		US-A- 4460592	17-07-84